[go: up one dir, main page]

NZ537304A - Ring-substituted diphenyl azetidinones, method for the production thereof, medicaments containing said compounds, and use thereof - Google Patents

Ring-substituted diphenyl azetidinones, method for the production thereof, medicaments containing said compounds, and use thereof

Info

Publication number
NZ537304A
NZ537304A NZ537304A NZ53730403A NZ537304A NZ 537304 A NZ537304 A NZ 537304A NZ 537304 A NZ537304 A NZ 537304A NZ 53730403 A NZ53730403 A NZ 53730403A NZ 537304 A NZ537304 A NZ 537304A
Authority
NZ
New Zealand
Prior art keywords
alkyl
crc6
phenyl
cooh
radical
Prior art date
Application number
NZ537304A
Inventor
Gerhard Jaehne
Wendelin Frick
Stefanie Flohr
Andreas Lindenschmidt
Heiner Glombik
Werner Kramer
Huber Heuer
Hans-Ludwig Schaefer
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of NZ537304A publication Critical patent/NZ537304A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Described is a compound of formula I, wherein R1, R2, R3, R4, R5, and R6, independently of one another, are chosen from:(C1-C30)-alkylene-(LAG)n, wherein at least one carbon atom of the alkylene radical is replaced by aryl or heteroaryl radicals, which may be substituted up to three times by R7, or by (C3-C10)-cycloalkyl or heterocycloalkyl radicals, which may be substituted up to four times by R7, and wherein at least one carbon atom of the alkylene radical may be replaced by -S(O)n-, where n=0-2, -O-, -(C-O)-, -(C=S)-, -CH=CH-, -Ca"C-, -N((C1-C6)-alkyl)-, -N(phenyl), -N((C1-C6)-alkyl-phenyl)-, -N(CO-(CH2)1-10-COOH)- and -NH-; or H, F, Cl, Br, I, CF3, NO2, N3, CN, COOH, COO(C1-C6)-alkyl, CONH2, CONH(C1-C6)-alkyl, CON[(C1-C6)-alkyl]2, (C1-C6)-alkyl, (C2-C6)-alkenyl, (C2C6)-alkynyl, or O-(C1-C6)-alkyl, where at least one hydrogen in the alkyl radical is replaced by fluorine; or SO2-NH2, SO2NH(C1-C6)-alkyl, SO2N[(C1-C6)-alkyl]2, S-(C1-C6)-alkyl, S-(CH2)n-phenyl, SO-(C1-C6)-alkyl, SO-(CH2)n-phenyl, SO2-(C1-C6)-alkyl, or SO2-(CH2)n-phenyl; wherein n=0-6, and the phenyl radical is may be substituted one or two times, each substituent chosen independently from: F, Cl, Br, OH, CF3, NO2, CN, OCF3, O-(C1-C6)-alkyl, (C1-C6)-alkyl, and NH2; or NH2, NH-(C1-C6)-alkyl, N((C1-C6)-alkyl)2, NH(C1-C7)-acyl, phenyl, or O-(CH2)n-phenyl, wherein n=0-6, and wherein the phenyl ring may be substituted up to three times, each substituent chosen independently from: F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, O-(C1-C6)-alkyl, (C1-C6)-alkyl, NH2, NH(C1-C6)-alkyl, N((C1-C6)-alkyl)2, SO2-CH3, COOH, COO-(C1-C6)-alkyl, and CONH2. Also mentioned is the use of one or more of the compounds of formula I as a medicament which normalize lipid metabolism and for treating hyperlipidemia, arteriosclerotic manifestations, insulin resistances or lowering the serum cholesterol concentration.

Description

New Zealand Paient Spedficaiion for Paient Number 537304 1 Description Ring-substituted diphenyl azetidinones, method for the production thereof, medicaments containing said compounds, and use thereof The invention relates to ring-substituted diphenylazetidinones, to their physiologically acceptable salts and to derivatives having physiological functions.
Diphenylazetidinones (such as, for example, ezetimibe) and their use for treating hyperlipidemia and arteriosclerosis and hypercholesterolemia have already been described [cf. Drugs of the Future 2000, 25(7):679-685) and US 5,756,470].
It was an object of the invention to provide further compounds having a therapeutically utilizable hypolipidemic action. In particular, it was an object to find novel compounds which, compared to the compounds described in the prior art, are absorbed to a very low extent. Very low absorption is to be understood as meaning an intestinal absorption of less than 10%, preferably less than or equal to 5%.
In particular, absorption of the novel compounds must be less than that of ezetimibe. Pharmaceutical^ active compounds which are absorbed to a low extent generally have considerably fewer side-effects.
REPLACEMENT SHEET (RULE 26) Accordingly, the invention relates to compounds of the formula I R1 R6 RE R2 R3 R4 in which R1, R2, R3, R4, R5, R6 independently of one another are (C1-C30)- alkylene-(LAG)n, where n = 1 - 5 and where one or more carbon atoms of the alkylene radical are replaced by aryl or heteroaryl radicals substituted up to three times by R7, or by (C3-Ci0)-cycloalkyl or heterocycloalkyl radicals substituted up to four times by R7 and one or more carbon atoms of the alkylene radical may be replaced by —S(0)n-, where n = 0 - 2, -0-, -(C=0)-, -(C=S)-, -CH=CH-, -CEC-, -N((CrC6)-alkyl)-, -N(phenyl), -N((CrC6)-alkyl-phenyl)-, -N(CO-(CH2)i-i0-COOH)- or -NH-; H, F, CI, Br, I, CF3, N02) N3j CN, COOH, COCKCrCeO-alkyl, CONH2) CONH(CrC6)-alkyl, CON[(CrC6)-alkyl]2, (CrC6)-alkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, 0-(C-i-C6)-alkyl, where one, more or all hydrogens in the alkyl radicals may be replaced by fluorine; S02-NH2, S02NH(Ci-C6)-alkyl, SOsNKCrCeJ-alkylk , S-(CrC6)-alkyl, S-(CH2)n-phenyl, SO-(CrC6)-alkyl, SO-(CH2)n-phenyl, S02-(Ci-C6)-alkyl, S02-(CH2)n-phenyl, where n = 0 - 6 and the phenyl radical may be REPLACEMENT SHEET (RULE 26) 3 substituted up to two times by F, CI, Br, OH, CF3, NO2, CN, OCF3, O-(CrC6)-alkyl, (CrC6)-alkyl, NH2; NH2, NH-(CrC6)-alkyl, N((CrC6)-alkyl)2, NH(Ci-C7)-acyl, phenyl, O-(CH2)n-phenyl, where n = 0 - 6, where the phenyl ring may be mono- to 5 trisubstituted by F, CI, Br, I, OH, CF3, N02, CN, OCF3, 0-(Ci-C6)-alkyl, (Ci-C6)-alkyl, NH2, NH(Ci-C6)-alkyl, N((Ci-C6)-alkyl)2, S02-CH3, COOH, COO-(Ci-C6)-alkyl, CONH2; R7 is F, CI, Br, I, CF3, N02, N3, CN, COOH, COO(CrC6)-alkyl, CONH2, CONH(CrC6)-alkyl, CON[(CrC6)-alkyl]2, (CrC6)-alkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, 0-(Ci-C6)-alkyl, where one, more or all hydrogens in the alkyl radicals may be replaced by fluorine; P03H2, S03H, S02-NH2, S02NH(CrC6)-alkyl, S02N[(CrC6)-alkyl]2 , S-(CrC6)-alkyl, S-(CH2)n-phenyl, SO-(Ci-C6)-alkyl, SO-(CH2)n-phenyl, 15 S02-(CrC6)-alkyl, S02-(CH2)n-phenyl, where n = 0 - 6 and the phenyl radical may be substituted up to two times by F, CI, Br, OH, CF3, N02, CN, OCF3, 0-(CrC6)-alkyl. (Ci-C6)-alkyl, NH2; C(NH)(NH2), NH2, NH-(CrC6)-alkyl, N((Ci-C6)-alkyl)2, NH(CrC7)-acyl, phenyl, 0-(CH2)n-phenyl, where n = 0 - 6, where the phenyl ring may be 20 mono- to trisubstituted by F, CI, Br, I, OH, CF3, N02, CN, OCF3, 0-(Ci- C6)-alkyl, (CrC6)-alkyl, NH2, NH(CrC6)-alkyl, N((CrC6)-alkyl)2, S02-CH3, COOH, COO-(Ci-C6)-alkyl, CONH2; (LAG)n is a sugar residue, disugar residue, trisugar residue, tetrasugar residue; 25 a sugar acid, an amino sugar; an amino acid residue, an oligopeptide residue comprising 2 to 9 amino acids; an acyclic, mono-, di- or tricyclic trialkylammonium radical, an acyclic mono-, di- or tricyclic trialkylammoniumalkyl radical, -0-(S02)-0H; 30 -(CH2)0-io-S03H;-(CH2)o-io-P(0)(OH)2,-(CH2)0.i0-O-P(O)(OH)2, -(CH2)0.io-COOH, -(CH2)O-IO-C(=NH)(NH2); -(CH2)0-IO-C(=NH)(NHOH); - REPLACEMENT SHEET (RULE 26) 4 NR8-C(=NR9)(NR10R11); where n = 1 -5 and R8, R9, R10 and R11 independently of one another may be H, (C-i-C6)-alkyl, phenyl, (C-i-Ce)-alkyl-phenyl, (C3-C8)-cycloalkyl), . and where in each case at least one of the radicals R1 to R6 must have the meaning (CrC3o)-alkylene-(LAG)n> where n = 1 - 5 and one or more carbon atoms of the alkylene radical are replaced by aryl or heteroaryl radicals substituted up to three times by R7, or by (C3-Cio)-cycloalkyl or heterocycloalkyl radicals substituted up to four times by R7 and one or more carbon atoms of the alkylene radical may be 10 replaced by -S(0)n-, where n = 0 - 2, -0-, -(C=0)-, -(C=S)-, -CH=CH-, -CEC-, -N((Ci-C6)-alkyl)-, -N(phenyl)-, -N((Ci-C6)-alkyl-phenyl)-, -N(CO-(CH2)i-io-COOH)- or -NH-; and their physiologically acceptable salts.
Preference is given to compounds of the formula I where at least one of the radicals R1 to R6 the meaning (CrC30)-alkylene-(LAG)n, where n = 1 - 5 and one or more carbon atoms of the alkylene radical are replaced by aryl or heteroaryl radicals substituted up to three times by R7, or by (C3-Cio)-cycloalkyl or heterocycloalkyl radicals substituted up to four times by R7 and one or more carbon atoms of the 20 alkylene radical may be replaced by -S(0)n-, where n = 0 - 2, -0-, -(C=0)-, -(C=S)-, -CH=CH-, -CEC-, -N((Ci-C6)-alkyl)-, -N(phenyl)-, -N((CrC6)-alkyl-phenyl)-, -N(CO-(CH2)i-io-COOH)- or -NH-.
Particular preference is given to compounds of the formula I where one of the 25 radicals R1 or R3 the meaning (C1-C3o)-alkylene-(LAG), where one or more carbon atoms of the alkylene radical are replaced by aryl or heteroaryl radicals substituted up to three times by R7, or by (C3-C-io)-cycloalkyl or heterocycloalkyl radicals substituted up to three times by R7 and one or more carbon atoms of the alkylene radical may be replaced by -S(0)n-, where n = 0 - 2, -0-, -(C=0)-, -N(CH3)-, -30 N(phenyl)-, -N(CO-(CH2)i-io-COOH)- or -NH-.
REPLACEMENT SHEET (RULE 26) Very particular preference is given to compounds of the formula I where at least one of the radicals R1 or R3 the meaning -(CH2)o-rNH-(C=0)o-i-(Co-C25)-alkylene-(C=O)0-i-N(R13)0-i-(LAG) or -(CH2)o-r(C=0)o-i-NH-(Co-C25)-alkylene-(C=0)o-i-N(R13)0-i-(LAG); where one or more carbon atoms of the alkylene radical are replaced by aryl or heteroaryl radicals substituted up to three times by R7, or by (C3-Cio)-cycloalkyl or heterocycloalkyl radicals substituted up to three times by R7 and one or more carbon atoms of the alkylene radical may be replaced by oxygen atoms, NH, N(CH3) or S02 , and where R13 may be H or CH3.
Preference is furthermore given to compounds of the formula I where the group LAG is a monosugar residue, an acyclic mono-, di- or tricyclic trialkylammoniumalkyl radical, a sulfonic acid or a carboxylic acid.
An aryl radical is to be understood as meaning a phenyl, naphthyl, biphenyl, tetrahydronaphthyl, alpha or beta-tetralone, indanyl or indan-1-onyl radical.
A heteroaryl radical is to be understood as meaning a pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyridazin-3-onyl, pyrrolyl, imidazolyl, pyrazolyl, 1,2,4-triazolyl, indolyl, 20 benzimidazolyl, thienyl, furyl, thiazolyl, oxazolyl, isoxazolyl or isothiazolyl radical.
Heterocycloalkyl radicals are to be understood as meaning (C3-Cio)-cycloalkyl radicals in which at least one and up to three carbon atoms independently of one another are replaced by NR8, O or S(0)n, where n = 0 - 2. Examples are the 25 azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, 1,4-dioxanyl, tetrahydrofuryl, piperazinyl or thiepanyl radical.
An acyclic trialkylammonium radical is to be understood as meaning the following group REPLACEMENT SHEET (RULE 26) 6 Alk, '(CH^)n / Alkj, H in which n = 0 to 10 and Alki and Alk2 independently of one another each denote a straight-chain or branched alkyl radical having 1 to 20 carbon atoms.
An acyclic trialkylammoniumalkyl radical is to be understood as meaning the following group Alki '(CHjJn / Alk- \ Alkg in which n = 0 to 10 and Alki, Alk2, Alk3 independently of one another each denote a 10 straight-chain or branched alkyl radical having 1 to 20 carbon atoms.
A mono- or di- or tricyclic trialkylammonium radical is to be understood as meaning, for example, radicals such as (CH2)m J^hJ 2 (CH2)m-|-N N+ / / H —7r;H Vn (CH2)p (CH2)m Vv,,vlll- HV(CH2)p (CH2)n" Qr (CH2)n Q(. "(CH2)n where n, m and p independently of one another can be 0 - 10 and one or more CH2 groups independently of one another may be replaced by O, S(0)n, where n = 0-2, NH, N-(CrC10)-alkyl, N-phenyl or N-CH2-phenyl.
A mono- or dicyclic trialkylammoniumalkyl radical is to be understood as meaning, 20 for example, radicals such as REPLACEMENT SHEET (RULE 26) 7 Alk, -N- -(CH,)m (CH2)p Y (CH2)m :n: Alk., or or CH2)n (CH2)n or or (CH2)n (CH2)n (CH2)i^^<>jCH2)m (CH2)^C^j^jCH2)m ^V"Aik1 Alk^ ^Alk, or (CH,)m (CH2)n . , ) L^Mk( (CH2)P where n, m and p independently of one another can be 0 - 10 and one or more CH2 groups independently of one another may be replaced by O, S(0)n, where n = 0-2, NH, N-(Ci-C-io)-alkyl, N-phenyl or N-CH2-phenyl and Alki is a straight-chain or branched alkyl radical having 1 to 20 carbon atoms.
Owing to their increased solubility in water, compared to the parent compounds, pharmaceutical^ acceptable salts are particularly suitable for medical applications. These salts must have a pharmaceutical^ acceptable anion or cation. Suitable 10 pharmaceutical^ acceptable acid addition salts of the compounds according to the invention are salts of inorganic acids, such as hydrochloric acid, hydrobromic acid, phosphoric acid, metaphosphoric acid, nitric acid, sulfonic acid and sulfuric acid, and of organic acids, such as acetic acid, benzenesulfonic acid, benzoic acid, citric acid, ethanesulfonic acid, fumaric acid, gluconic acid, glycolic acid, isothionic acid, lactic 15 acid, lactobionic acid, maleic acid, malic acid, methanesulfonic acid, succinic acid, p-toluenesulfonic acid, tartaric acid and trifluoroacetic acid, for example. For medical REPLACEMENT SHEET (RULE 26) 8 purposes, very particular preference is given to using the chloride salt. Suitable pharmaceutical^ acceptable basic salts are ammonium salts, alkali metal salts (such as sodium and potassium salts) and alkaline earth metal salts (such as magnesium and calcium salts).
The scope of the invention also includes salts having a pharmaceutical^ unacceptable anion, which salts may be useful intermediates for preparing or purifying pharmaceutically acceptable salts and/or for use in nontherapeutic, for example in vitro, applications. t Here, the term "derivative having physiological function" refers to any physiologically acceptable derivative of a compound according to the invention, for example an ester, that is able, upon administration to a mammal, for example man, to form such a compound or an active metabolite (directly or indirectly).
A further aspect of this invention are prodrugs of the compounds according to the invention. Such prodrugs can be metabolized in vivo to give a compound according to the invention. These prodrugs may or may not be active in their own right.
The compounds according to the invention can also be present in various polymorphous forms, for example as amorphous and crystalline polymorphous forms. The scope of the invention includes all polymorphous forms of the compounds according to the invention, which form a further aspect of the invention.
Hereinbelow, all references to "compound(s) of the formula (I)" refer to a compound or compounds of the formula (I) as described above, and to their salts, solvates and derivatives having physiological function, as described herein.
The compounds of the formula I and their pharmaceutically acceptable salts and derivatives having physiological function are ideal medicaments for treating an impaired lipid metabolism, in particular hyperlipidemia. The compounds of the REPLACEMENT SHEET (RULE 26) 9 formula I are also suitable for modulating the serum cholesterol concentration and for preventing and treating arteriosclerotic manifestations.
The compound(s) of the formula (I) can also be administered in combination with 5 other active compounds.
The amount of a compound of the formula (I) required to achieve the desired biological effect depends on a number of factors, for example on the specific compound chosen, on the intended use, on the mode of administration and on the 10 clinical condition of the patient. In general, the daily dose is in the range from 0.1 mg 0 to 100 mg (typically from 0.1 mg to 50 mg) per day per kilogram of bodyweight, for example 0.1-10 mg/kg/day. Tablets or capsules may contain, for example, from 0.01 to 100 mg, typically from 0.02 to 50 mg. In the case of pharmaceutically acceptable salts, the abovementioned weight data relate to the weight of the diphenyl-15 azetidinone-ion derived from the salt. For the prophylaxis or therapy of the abovementioned conditions, the compounds of the formula (I) can be used themselves as the compound, but preferably they are present in the form of a pharmaceutical composition with an acceptable carrier. The carrier must of course be acceptable in the sense that it is compatible with the other constituents of the 20 composition and is not harmful to the health of the patient. The carrier can be a solid or a liquid or both and is preferably formulated with the compound as an individual ^ dose, for example as a tablet, which can contain from 0.05% to 95% by weight of the active compound. Further pharmaceutically active substances can also be present, including further compounds of the formula (I). The pharmaceutical compositions 25 according to the invention can be prepared by one of the known pharmaceutical methods, which essentially consist in mixing the constituents with pharmacologically acceptable carriers and/or auxiliaries.
Pharmaceutical compositions according to the invention are those which are suitable 30 for oral or peroral (e.g. sublingual) administration, although the most suitable manner of administration is dependent in each individual case on the nature and severity of REPLACEMENT SHEET (RULE 26) the condition to be treated and on the type of the compound of the formula (I) used in each case. Coated forrnulations and coated delayed-release formulations are also included in the scope of the invention. Acid-resistant and enteric formulations are preferred. Suitable enteric coatings include cellulose acetate phthalate, polyvinyl 5 • acetate phthalate, hydroxypropylmethylcellulose phthalate and anionic polymers of methacrylic acjd and methyl methacrylate.
Suitable pharmaceutical compounds for oral administration can be present in separate units, such as, for example, capsules, cachets, lozenges or tablets, which 10 in each case contain a specific amount of the compound of the formula (I); as a powder or granules; as a solution or suspension in an aqueous or nonaqueous liquid; or as an oil-in-water or water-in-oil emulsion. As already mentioned, these compositions can be prepared according to any suitable pharmaceutical method which includes a step in which the active compound and the carrier (which can 15 consist of one or more additional constituents) are brought into contact. In general, the compositions are prepared by uniform and homogeneous mixing of the active compound with a liquid and/or finely divided solid carrier, after which the product, if necessary, is shaped. For example, a tablet can thus be prepared by pressing or shaping a powder or granules of the compound, if appropriate with one or more 20 additional constituents. Pressed tablets can be produced by tableting the compound in free-flowing form, such as, for example, a powder or granules, if appropriate mixed ^ with a binder, lubricant, inert diluent and/or a (number of) surface-active/ dispersing agent(s) in a suitable machine. Shaped tablets can be produced by shaping the pulverulent compound moistened with an inert liquid diluent in a suitable 25 machine.
Pharmaceutical compositions which are suitable for peroral (sublingual) administration include lozenges which contain a compound of the formula (I) with a flavoring, customarily sucrose and gum arabic or tragacanth, and pastilles which 30 include the compound in an inert base such as gelatin and glycerol or sucrose and gum arabic.
REPLACEMENT SHEET (RULE 26) 11 Suitable other active compounds for the combination preparations are: all antidiabetics mentioned in Rote Liste 2001, Chapter 12. They can be combined with the compounds of the formula I according to the invention in particular to 5 achieve a synergistically enhanced action. The active compound combination can be administered either by separate administration of the active compounds to the patient or in the form of combination preparations comprising a plurality of active compounds in a pharmaceutical preparation.
Antidiabetics include insulin and insulin derivatives, such as, for example, Lantus® or 0 HMR 1964, GLP-1 derivatives, such as, for example, those disclosed by Novo Nordisk A/S in WO 98/08871, and oral hypoglycemic active compounds.
The oral hypoglycemic active compounds preferably include sulfonylureas, 15 biguadines, meglitinides, oxadiazolidinediones, thiazolidinediones, glucosidase inhibitors, glucagon antagonists, GLP-1 agonists, potassium channel openers, such as, for example, those disclosed by Novo Nordisk A/S in WO 97/26265 and WO 99/03861, insulin sensitizers, inhibitors of liver enzymes involved in stimulating gluconeogenesis and/or glycogenolysis, modulators of glucose uptake, compounds 20 which modulate lipid metabolism, such as antihyperlipidemic active compounds and antilipidemic active compounds, compounds which reduce food intake, PPAR and ^ PXR agonists and active compounds which act on the ATP-dependent potassium channel of the beta cells.
In one embodiment of the invention, the compounds of the formula I are administered in combination with an HMGCoA reductase inhibitor such as simvastatin, fluvastatin, pravastatin, lovastatin, atorvastatin, cerivastatin, rosuvastatin.
In one embodiment of the invention, the compounds of the formula I are administered in combination with a cholesterol absorption inhibitor, such as, for REPLACEMENT SHEET (RULE 26) 12 example, ezetimibe, tiqueside, pamaqueside.
In one embodiment of the invention, the compounds of the formula I are administered in combination with a PPAR gamma agonist, such as, for example, 5 • rosiglitazone, pioglitazone, JTT-501, Gl 262570.
In one embodiment of the invention, the compounds of the formula I are administered in combination with a PPAR alpha agonist, such as, for example, GW 9578, GW 7647.
In one embodiment of the invention, the compounds of the formula I are administered in combination with a mixed PPAR alpha/gamma agonist, such as, for example, GW 1536, AVE 8042, AVE 8134, AVE 0847.
In one embodiment of the invention, the compounds of the formula I are administered in combination with a fibrate, such as, for example, fenofibrate, clofibrate, bezafibrate.
In one embodiment of the invention, the compounds of the formula I are 20 administered in combination with an MTP inhibitor, such as, for example, Bay 13-9952, BMS-201038, R-103757.
• In one embodiment of the invention, the compounds of the formula I are administered in combination with a bile acid absorption inhibitor, such as, for 25 example, HMR 1453.
In one embodiment of the invention, the compounds of the formula I are administered in combination with a CETP inhibitor, such as, for example, Bay 194789.
In one embodiment of the invention, the compounds of the formula I are REPLACEMENT SHEET (RULE 26) 13 administered in combination with a polymeric bile acid adsorber, such as, for example, cholestyramine, colesolvam.
In one embodiment of the invention, the compounds of the formula I are 5 administered in combination with an LDL receptor inducer, such as, for example, HMR1171, HMR1586.
In one embodiment of the invention, the compounds of the formula I are administered in combination with an ACAT inhibitor, such as, for example, 10 avasimibe.
In one embodiment of the invention, the compounds of the formula I are administered in combination with an antioxidant, such as, for example, OPC-14117.
In one embodiment of the invention, the compounds of the formula I are administered in combination with a lipoprotein lipase inhibitor, such as, for example, NO-1886.
In one embodiment of the invention, the compounds of the formula I are 20 administered in combination with an ATP citrate lyase inhibitor, such as, for example, SB-204990.
• In one embodiment of the invention, the compounds of the formula I are administered in combination with a squalene synthetase inhibitor, such as, for 25 example, BMS-188494.
In one embodiment of the invention, the compounds of the formula I are administered in combination with a lipoprotein(a) antagonist, such as, for example, CI-1027 or nicotinic acid.
In one embodiment of the invention, the compounds of the formula I are REPLACEMENT SHEET (RULE 26) 14 administered in combination with a lipase inhibitor, such as, for example, Orlistat.
In one embodiment of the invention, the compounds of the formula I are administered in combination with insulin.
• In one embodiment, the compounds of the formula I are administered in combination with a sulfonylurea, such as, for example, tolbutamide, glibenclamide, glipizide or gliclazide.
In one embodiment, the compounds of the formula I are administered in combination with a biguanide, such as, for example, metformin.
In another embodiment, the compounds of the formula I are administered in 0 combination with a meglitinide, such as, for example, repaglinide.
In one embodiment, the compounds of the formula I are administered in combination with a thiazolidinedione, such as, for example, troglitazone, ciglitazone, pioglitazone, rosiglitazone, or the compounds disclosed by Dr. Reddy's Research Foundation in 15 WO 97/41097, in particular 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl-methoxy]phenyl]methyl]-2,4-thiazolidinedione.
In one embodiment, the compounds of the formula I are administered in combination with an a-glucosidase inhibitor, such as, for example, miglitol or acarbose.
In one embodiment, the compounds of the formula I are administered in combination 20 with an active compound which acts on the ATP-dependent potassium channel of beta cells, such as, for example, tolbutamide, glibenclamide, glipizide, gliazide or ^ repaglinide.
In one embodiment, the compounds of the formula I are administered in combination with more than one of the abovementioned compounds, for example in combination 25 with a sulfonylurea and metformin, a sulfonylurea and acarbose, repaglinide and metformin, insulin and a sulfonylurea, insulin and metformin, insulin and troglitazon, insulin and lovastatin, etc.
In a further embodiment, the compounds of the formula I are administered in 30 combination with CART agonists, NPY agonists, MC3 and MC4 agonists, orexin agonists, H3 agonists, TNF agonists, CRF agonists, CRF BP antagonists, urocortin REPLACEMENT SHEET (RULE 26) agonists, p3-agonists, MCH (melanine-concentrating hormone) antagonists, CCK agonists, serotonin reuptake inhibitors, mixed serotonin and noradrenergic compounds, 5HT agonists, bombesin agonists, galanin antagonists, growth hormone, growth hormone-releasing compounds, TRH agonists, decoupling protein 5 2 or 3.modulators, leptin agonists, DA agonists (bromocriptine, doprexin), lipase/amylase inhibitors, PPAR modulators, RXR modulators or TR-p agonists.
In one embodiment of the invention, the further active compound is leptin.
In one embodiment, the further active compound is dexamphetamine or 10 amphetamine. 0 In one embodiment, the further active compound is fenfluramine or dexfenfluramine. In another embodiment, the further active compound is sibutramine.
In one embodiment, the further active compound is Orlistat.
In one embodiment, the further active compound is mazindol or phentermine.
In one embodiment, the compounds of the formula I are administered in combination with fiber, preferably insoluble fiber, such as, for example, Caromax®. The combination with Caromax® can be given in one preparation or by separate administration of compounds of the formula I and Caromax®. Here, Caromax® can 20 also be administered in the form of food, such as, for example, in bakery goods or ^ muesli bars. Compared to the individual active compounds, the combination of ™ compounds of the formula I with Caromax® is, in addition to an enhanced action, in particular with respect to the lowering of LDL cholesterol, also characterized by its improved tolerability.
It goes without saying that each suitable combination of the compounds according to the invention with one or more of the compounds mentioned above and optionally one or more further pharmacologically active substances is included in the scope of the present invention.
The invention furthermore provides both stereoisomer mixtures of the formula I and REPLACEMENT SHEET (RULE 26) 16 the pure stereoisomers of the formula I, and diastereomer mixtures of the formula I and the pure diastereomers. The mixtures are separated by chromatographic means.
• Preference is given to both racemic and enantiomerically pure compounds of the formula I of the following structure: Sugar residues are to be understood as meaning compounds which are derived from 10 aldoses and ketoses which have 3 to 7 carbon atoms and may belong to the D or the L series; also included are amino sugars, sugar alcohols or sugar acids. Glucose, mannose, fructose, galactose, ribose, erythrose, glycerolaldehyde, sedoheptulose, glucosamine, galactosamine, glucuronic acid, galacturonic acid, gluconic acid, galactonic acid, mannonic acid, glucamine, 3-amino-1,2-propanediol, glucaric acid and galactaric acid may be mentioned by way of example.
Disugars are saccharides composed of two sugar units. Di-, tri- or tetrasaccharides are formed by acetal-like binding of two or more sugars. Here, the bonds may be in the a- or p-form. Lactose, maltose and cellobiose may be mentioned by way of 20 example.
If the sugar is substituted, the substitution is preferably at the hydrogen atom of an OH group of the sugar.
R4 REPLACEMENT SHEET (RULE 26) 17 Suitable protective groups for the hydroxyl groups of the sugars are substantially: benzyl, acetyl, benzoyl, pivaloyl, trityl, tert-butyldimethylsilyl, benzylidene, cyclohexylidene or isopropylidene protective groups.
The term "amino acids" or "amino acid residues" refers, for example, to the stereoisomeric forms, i.e. the D or L forms, of the following compounds: alanine cysteine aspartic acid glutamic acid phenylalanine tryptophan tyrosine glycine histidine isoleucine lysine leucine methionine asparagine proline glutamine arginine serine threonine valine 2-aminoadipic acid 2-aminoisobutyric acid 3-aminoadipic acid 3-aminoisobutyric acid beta-alanine 2-aminopimelic acid 2-aminobutyric acid 2,4-diaminobutyric acid • 4-aminobutyric acid desmosine piperidine carboxylic acid 2,2-diaminopimelic acid 6-aminocaproic acid 2,3-diaminopropionic acid 2-aminoheptanoic acid N-ethylglycine 2-(2-thienyl)glycine 3-(2-thienyl)alanine penicillamine sarcosine N-ethylasparagine N-methylisoleucine hydroxylysine 6-N-methyllysine allo-hydroxylysine N-methylvaline 3-hydroxyproline norvaline 4-hydroxyproline norleucine REPLACEMENT SHEET (RULE 26) 18 isodesmosine ornithine allo-isoieucine N-methylglycine , For abbreviating the amino acids, the conventional notation was used (cf. Schroder, Lubke, The Peptides, Volume I, New York 1965, pages XXII-XXIII; Houben-Weyl, Methoden der Organischen Chemie [Methods of organic chemistry], Volume XV/1 and 2, Stuttgart 1974). The amino acid pGlu denotes pyroglutamyl, Nal denotes 3-(2-naphthyl)alanine, azagly-NH2 denotes a compound of the formula NH2-NH-CONH2 10 and D-Asp denotes the D form of aspartic acid. According to their chemical nature, peptides are acid amides, and on hydrolysis they decompose into amino acids.
An oligopeptide is to be understood as meaning a peptide constructed of 2 to 9 of the amino acids mentioned above.
Suitable protective groups (see, for example, T.W. Greene, "Protective Groups in Organic Synthesis") for amino acids are primarily: Arg(Tos), Arg(Mts), Arg(Mtr), Arg(PMV), Asp(OBzl), Asp(OBut), Cys(4-MeBzl), Cys(Acm), Cys(SBut), Glu(Obzl), Glu(Obut), His(Tos), His(Fmoc), His(Dnp), His(Trt), 20 Lys(CI-Z), Lys(Boc), Met(O), Ser(Bzl), Ser(But), Thr(Bzl), Thr(But), Trp(Mts), Trp(CHO), Tyr(Br-Z), Tyr(Bzl) or Tyr(But). t Amino protective groups that are preferably used are the benzyloxycarbonyl (Z) radical, which can be removed by catalytic hydrogenation, the 2-(3,5-25 dimethyloxyphenyl)propyl(2)oxycarbonyl(Ddz) or trityl (Trt) radical, which can be removed by weak acids, the t-butylcarbamate (BOC) radical, which can be removed by 3M hydrochloric acid, and the 9-fluorenyImethyloxycarbonyl (Fmoc) radical, which can be removed using secondary amines.
REPLACEMENT SHEET (RULE 26) 19 The invention furthermore relates to a process for preparing diphenylazetidinone derivatives of formula I.
'-J0-6 (lag) Y can be S, O, (C=0), (C=S), CH=CH, CEC, N((CrC6)-alkyl), N(phenyl), N((CrC6)-alkyl-phenyl), N(CO-(CH2)i-io-COOH) or NH; R12 can be H or, if Y = (C=0) or (C=S), OH; W can, independently of Y, be an up to trisubstituted aryl or heteroaryl radical or an 10 up to tetrasubstituted (C3-Ci0)-cycloalkyl or heterocycloalkyl radical or -S(0)n-, where n = 0 - 2, -0-, -(C=0)-, -(C=S)-, -CH=CH-, -CEC-, -N((CrC6)-alkyl)-, -N(phenyl), -N((Ci-C6)-alkyl-phenyl)-, -N(CO-(CH2)i-io-COOH)- or -NH- or a bond; v, x, y and z independently of one another can be 0 to 10.
In compound II, -(CH2)x-Y-R12 can alternatively also be attached to one of the other 15 two phenyl rings.
The process for preparing compounds of the formula I comprises, for example, reacting an amine of the formula II with an alkylating or acylating agent which, preferably in the omega position, carries a further functionality- if appropriate in 20 protected form. This functionality is (after deprotection) used for attaching (LAG), for example with the formation of ether, amine or amide bonds.
REPLACEMENT SHEET (RULE 26) The examples below serve to illustrate the invention in more detail, without limiting the invention to the products and embodiments described in the examples.
Example I • 2,3,4,5,6-Pentahydroxyhexylamide of 4-(4-{4-[3-[3-(4-fluorophenyl)-3-hydroxypropyl]-2-(4-methoxyphenyl)-4-oxoazetidin-1 -yl]benzylcarbamoyl}phenoxy)benzoic acid (7): ci- IO a) 3-[5-(tert-butyldimethylsilany!oxy)-5-(4-fluorophenyl)-pentanoyl]-4-phenyl-oxazolidin-2-one (1): 27 g of 3-[5-(4-fluorophenyl)-5-hydroxypentanoyl]-4-phenyloxazolidin-2-one, 13.6 g of tert-butyldimethylsilyl chloride and 10.2 g of imidazole are dissolved in 36 ml of dimethylformamide and stirred at 60°C for 90 min. After the reaction has ended, the mixture is dissolved in ethyl acetate and extracted two times with water. The organic phase is dried over magnesium sulfate, filtered and concentrated under reduced 20 pressure. This gives 3-[5-(tert-butyldimethylsilanyloxy)-5-(4-fluorophenyl)-pentanoyl]-4-phenyloxazolidin-2-one (1) of molecular weight 471.65 (C26H34FNC>4Si); MS (ESI): 340.28 (MH+- HOSi(CH3)2C(CH3)3).
REPLACEMENT SHEET (RULE 26) 21 b) 4-[5-(tert-butyldimethylsilanyloxy)-5-(4-fluorophenyl)-1-(4-methoxyphenyl)-2-(2-oxo- 4-phenyloxazolidine-3-carbonyl)pentylamino]benzonitrile (2): 16.2 g of 3-[5-(tert-butyldimethylsilanyloxy)-5-(4-fluorophenyl)-pentanoyl]-4-5 phenyloxazolidin-2-one (1) are dissolved in 350 ml of dichloromethane. 19.8 ml of Hunig base and 10.14 g of 4-[(4-methoxyphenylimino)methyl]benzonitrile are added, and the solution is cooled to -10°C. 8.52 ml of trimethylsilyl triflate are added to the cooled solution, and the mixture is stirred at -10°C for 30 min. The solution is then cooled to -30°C, and 44 ml of titanium tetrachloride solution are added. The reaction 10 mixture is stirred at from -30 to -40°C for 2 h. The solution is then allowed to warm to room temperature and the reaction solution is washed successively with 200 ml of 2N sulfuric acid, 300 ml of 20% strength sodium hydrogen sulfite solution and sat. sodium chloride solution. The organic phase is dried over magnesium sulfate and concentrated under reduced pressure, and the residue is purified on silica gel using 15 n-heptane/ethyl acetate 3/1. This gives 4-[5-(tert-butyldimethylsilanyloxy)-5-(4-fluorophenyl)-1-(4-methoxyphenyl)-2-(2-oxo-4-phenyloxazolidine-3-carbonyl)pentylamino]benzonitrile (2) of molecular weight 707.93 (C^HUeFlShOsSi); MS (ESI): 590.51 (MH+- C7H5N2). c) 4-[3-[3-(tert-butyldimethylsilanyloxy)-3-(4-fluorophenyl)propyl]-2-(4-methoxyphenyl)-4-oxoazetidin-1 -yl]benzonitrile (3): 13.2 g of 4-[5-(tert-butyldimethylsilanyloxy)-5-(4-fluorophenyl)-1 -(4-methoxyphenyl)-25 2-(2-oxo-4-phenyloxazolidine-3-carbonyl)pentylamino]benzonitrile (2) are dissolved in 380 ml of methyl tert-butylether, 18.6 ml of N,0-bis(trimethylsilyl)acetamide and 1.86 ml of a 1 M solution of tetrabutylammonium fluoride in tetrahydrofuran are added and the mixture is stirred at room temperature for 2 h. After the reaction has ended, 10 ml of acetic acid are added, the reaction mixture is concentrated under 30 reduced pressure and the residue is purified on silica gel using toluene/ethyl acetate 50/1. This gives 4-[3-[3-(tert-butyldimethylsilanyloxy)-3-(4-fluorophenyl)propyl]-2-(4- REPLACEMENT SHEET (RULE 26) 22 methoxyphenyl)-4-oxoazetidin-1-yl]-benzonitrile (3) of molecular weight 544.75 (C32H37FN203Si); MS (ESI): 545.56 (M+H+). d) 4-[3-[3-(4-Fluorophenyl)-3-hydroxypropyl]-2-(4-methoxyphenyl)-4-oxoazetidin-1-yl]- benzonitrile (4): 3.5 g of 4-[3-[3-(tert-butyldimethylsilanyloxy)-3-(4-fluorophenyl)propyl]-2-(4-methoxyphenyl)-4-oxoazetidin-1-yl]-benzonitrile (3) are dissolved in 65 ml of 10 tetrahydrofuran, 0.74 ml of acetic acid and 8.03 ml of a 1 M solution of 0 tetrabutylammonium fluoride in tetrahydrofuran are added and the mixture is stirred at room temperature for 2 h. Another 4.82 ml of the tetrabutylammonium fluoride solution are then added, and the mixture is stirred at reflux temperature for another 3 h. The cooled reaction mixture is concentrated under reduced pressure and the 15 residue is purified by silica gel chromatography using n-heptane/ethyl acetate 2/1. This gives 4-[3-[3-(4-fluorophenyl)-3-hydroxypropyl]-2-(4-methoxyphenyl)-4-oxoazetidin-1-yl]-benzonitrile (4) of molecular weight 430.48 (C26H23FN2O3); MS (ESI): 431.24 (M+H+). e) 1-(4-Aminomethylphenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-methoxyphenyl)-azetidin-2-one (5): 1.22 g of 4-[3-[3-(4-fluorophenyl)-3-hydroxypropyl]-2-(4-methoxyphenyl)-4-25 oxoazetidin-1-yl]-benzonitrile (4) are dissolved in 90 ml of ethanol, 10 ml of conc. ammonia solution and an excess of Raney nickel are added, and the mixture is stirred at 60°C and a hydrogen pressure of 10 bar for 8 h. Overnight, the reaction mixture cools to room temperature, and the next day, the catalyst is removed, the filtrate is concentrated under reduced pressure and the residue is purified by silica 30 gel chromatography using dichloromethane/methanol/ammonia solution 10/1/0.1. This gives 1 -(4-aminomethylphenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl)-4-(4- REPLACEMENT SHEET (RULE 26) 23 methoxyphenyl)-azetidin-2-one (5) of molecular weight 434.51 (C26H27FN2O3); MS (ESI): 418.2 (MH+-NH3). t f) 2,3,4,5,6-Pentahydroxyhexylamide of 4,4'-oxybisbenzoic acid (6): At room temperature, 0.52 g of 4,4'-oxybisbenzoic acid and 0.36 g of D-glucamine are suspended in 10 ml of dry dimethylformamide, 0.31 g of HOBt and 0.39 g of EDC are added and the mixture is stirred at room temperature for 12 h. The reaction 10 mikture is evaporated to dryness and dried under high vacuum. The residue is ^ thoroughly titrated with water, the resulting suspension is filtered and the residue is titrated with methanol and filtered again. The filtrate is concentrated to half of its volume using a rotary evaporator, and the solution is cooled in an ice bath. The resulting precipitate is filtered off with suction, washed with a little ice-cooled 15 methanol and dried under reduced pressure. This gives the 2,3,4,5,6- pentahydroxyhexylamide of 4,4'-oxybisbenzoic acid (6) of molecular weight 421.40 (C20H23NO9); MS (ESI): 422.28 (MH+). g) 2,3,4,5,6-Pentahydroxyhexylamide of 4-(4-{4-[3-[3-(4-fluorophenyl)-3- hydroxypropyl]-2-(4-methoxyphenyl)-4-oxoazetidin-1 -£ yl]benzylcarbamoyl}phenoxy)benzoic acid (7): 87 mg of the compound prepared under e) and 90 mg of the compound prepared 25 under f) are, at room temperature, dissolved in 3 ml of dry dimethylformamide, 31 mg of HOBt and 39 mg of EDC are added and the mixture is stirred at room temperature for 12 h. The reaction mixture is evaporated to dryness under high vacuum and the residue is titrated with dichloromethane, filtered off with suction, washed with dichloromethane and dried under reduced pressure. This gives the 30 2,3,4,5,6-pentahydroxyhexylamide of 4-(4-{4-[3-[3-(4-fluorophenyl)-3-hydroxypropyl]- REPLACEMENT SHEET (RULE 26) 24 2-(4-methoxyphenyl)-4-oxoazetidin-1 -yl]benzylcarbamoyl}pherioxy)benzoic acid (7) with a molecular weight 837.90 (C46H48FN3O11); MS (ESI): 838,39 (MH+).
Example II 2,3,4,5,6-Pentahydroxyhexylamide of 4-(4-{4-[3-(3-hydroxy-3-phenylpropyl)-2-oxo-4-phenylazetidin-1-yl]benzylcarbamoyl}phenoxy)benzoic acid (9): a) 1-(4-Aminomethylphenyl)-3-(3-hydroxy-3-phenylpropyl)-4-phenylazetidin-2-one (8): This compound is prepared as described above for 1-(4-aminomethylphenyl)-3-[3-(4-15 fluorophenyl)-3-hydroxypropyl]-4-(4-methoxyphenyl)-azetidin-2-one, except that 3-[5-(tert-butyldimethylsilanyloxy)-5-phenylpentanoyl]-4-phenyloxazolidin-2-one and 4-(benzylideneamino)benzonitrile are used. This gives 1-(4-aminomethylphenyl)-3-(3-hydroxy-3-phenyipropyl)-4-phenylazetidin-2-one (8) of molecular weight 386.50 (CzsHzeNsOz); MS (ESI): 370.2 (MH+-NH3). b) 2,3,4,5,6-Pentahydroxyhexylamide of 4-(4-{4-[3-(3-hydroxy-3-phenylpropyl)-2-oxo-4-phenylazetidin-1 -yl]benzy!carbamoyl}phenoxy)benzoic acid (9): The benzylamine from I la is reacted with the 2,3,4,5,6-pentahydroxyhexylamide of 4,4'-oxybisbenzoic acid from If as described in Example I. This gives the 2,3,4,5,6- REPLACEMENT SHEET (RULE 26) pentahydroxyhexylamide of 4-(4-{4-[3-(3-hydroxy-3-phenylpropyl)-2-oxo-4-pheriylazetidin-1-yl]berizylcarbamoyl}phenoxy)benzoic acid (9) of molecular weight 789.89 (C45H47N3O10); MS (ESI): 790.26 (MH+).
Example III 2,3,4,5,6-Pentahydroxyhexylamide of 4-(4-{4-[3-[3-(4-fluorophenyl)-3-hydroxypropyl]-2-(4-methoxyphenyl)-4-oxoazetidin-1 -yl]-benzylcarbamoyl}-benzyl)-benzoic acid (10): The compound of Example III is obtained analogously to the procedure of Example I, except that the 2,3,4,5,6-pentahydroxyhexylamide of diphenylmethane-4,4'-dicarboxylic acid is used. This gives the 2,3,4,5,6-pentahydroxyhexylamide of 4-(4-{4-[3-[3-(4-fluorophenyl)-3-hydroxypropyl]-2-(4-methoxyphenyl)-4-oxoazetidin-1-yl]-benzylcarbamoyl}benzyl)benzoic acid (10) of molecular weight 835.93 (C47H5OFN3010); MS (ESI): 836.18 (MH+).
Example IV 1-[4-(4-{1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl}phenoxymethyl)benzyl]-4-aza-1 -azoniabicyclo[2.2.2]octane bromide (13): REPLACEMENT SHEET (RULE 26) 26 a) 4-[4-(4-Bromomethylbenzyloxy)phenyl]-1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3- hydroxypropyl]azetidin-2-one (12): 3.0 g of 1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)- azetidin-2-orie (11) 7.0 g of 1,4-bisbromomethylbenzene and 5.0 g of potassium carbonate are dissolved in 100 ml of dimethylformamide and stirred at room temperature for 90 min. After the reaction has ended, the mixture is dissolved in ethyl acetate and extracted two times with water. The organic phase is dried over magnesium sulfate, filtered and concentrated under reduced pressure. The residue is purified by flash chromatography (n-heptane/ethyl acetate). Yield 3.2 g of colorless crystals (12) of molecular weight 592.49 (CajHasB^NOa); MS (ESI): 592.2 (MH+). b) 1 -[4-(4-{1 -(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4- oxoazetidin-2- yl}phenoxymethyl)benzyl]-4-aza-1-azoniabicyclo[2.2.2]octane bromide (13): 180 mg of (12) and 300 mg of 1,4-diazabicyclo[2.2.2]octane (DABCO) are dissolved in 5ml of toluene and stirred at 80°C for 90 min. After the reaction has ended, the mixture is allowed to cool and the colorless solid is filtered off with suction. This gives REPLACEMENT SHEET (RULE 26) 27 195 mg of product (13) of molecular weight 704.66 (C38H4oBrF2N303); MS (ESI): 624.30 (MH+).
Example V 1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-{4-[(2,3,4,5,6~ pentahydroxyhexylamine)methyl]benzyloxy}phenyl)azetidiri-2-one (14) 60 mg of (12) and 150 mg of glucamine are dissolved in 5ml of dimethylformamide and stirred at 80°C for 90 min. After the reaction has ended the mixture is dissolved in ethyl acetate and extracted two times with water. The organic phase is dried over magnesium sulfate, filtered and concentrated under reduced pressure. The residue is purified by flash chromatography (methylene chloride/methanol/conc. ammonia 30/10/3). Yield 33 mg of a colorless solid (14) of molecular weight 692.76 (C38H42F2N208); MS (ESI): 693.5 (MH+).
Example VI 1-[2-(4-{1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl}phenoxymethyl)benzyl]-4-aza-1 -azoniabicyclo[2.2.2]octane bromide (16): REPLACEMENT SHEET (RULE 26) 28 a) 4-[4-(2-Bromomethylbenzyloxy)phenyl]-1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-azetidin-2-one (15): 1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-10 azetidin-2-one (11) is reacted with 1,2-bisbromomethylbenzene and potassium carbonate analogously to Example IV, giving a colorless solid (15) of molecular weight 592.49 (CaaHasBrFaNOa); MS (ESI): 592.2 (MH+). b) 1 -[4-(4-{1 -(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4- oxoazetidin-2- yl}phenoxymethyl)benzyl]-4-aza-1-azoniabicyclo[2.2.2]octane bromide (16): (15) and DABCO are dissolved in toluene and reacted analogously to Example IV, 20 giving the product (16) as a colorless solid of molecular weight 704.66 (CsaH^BrFaNsOa); MS (ESI): 624.30 (MH+).
REPLACEMENT SHEET (RULE 26) 29 Example VII 1-(4-Fluorophenyl)-3-[3-(4-fIuorophenyl)-3-hydroxypropyl]-4-(4-{2-[(2,3,4,5,6-pentahydroxyhexylamine)methyl]benzyloxy}phenyl)azetidin-2-one (17): HO ,OH • F (15) and glucamine are dissolved in dimethylformamide and reacted analogously to Example V, giving the product (17) as a colorless solid of molecular weight 692.76 10 (C38H42F2N208); MS (ESI): 693.5 (MH+).
Example VIII 1 -[3-(4-{1 ~(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl}phenoxymethyl)benzyl]-4-aza-1 -azoniabicyclo[2.2.2]octane bromide (19): a) 4-[4-(3-Bromomethylbenzyloxy)phenyl]-1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3- hydroxypropyl]azetidin-2-one (18): REPLACEMENT SHEET (RULE 26) 1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one (11) is reacted with 1,3-bisbromomethylbenzene and 5 potassium carbonate analogously to Example IV, giving a colorless solid (18) of molecular weight 592.49 (C32H28BrF2N03); MS (ESI): 592.2 (MH+). • b) 1 -[3-(4-{1 -(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-10 oxoazetidin-2- yl}phenoxymethyl)benzyl]-4-aza-1 -azoniabicyclo[2.2.2]octane bromide (19): (18) and DABCO are dissolved in toluene and reacted analogously to Example IV, giving the product (19) as a colorless solid of molecular weight 704.66 15 (C38H4oBrF2N303); MS (ESI): 624.30 (MH+).
Example IX 1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-{3-[(2,3,4,5,6-pentahydroxyhexylamine)methyl]benzyloxy}phenyl)azetidin-2-one (20): REPLACEMENT SHEET (RULE 26) 31 (18) and glucamine are dissolved in dimethylformamide and reacted analogously to Example V, giving the product (20) as a colorless solid of molecular weight 692.76 (C38H42F2N208); MS (ESI): 693.5 (MH+).
Example X 1-[4'-(4-{1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl}phenoxymethyl)biphenyl-4-ylmethyl]-4-aza-1-azoniabicyclo[2.2.2]octane bromide a) 4-[4-(4,-Bromomethylbiphenyl-4-ylmethoxy)phenyl]-1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]azetidin-2-one (21): 1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-azetidin-2-one (11) is reacted with 4,4'-bisbromomethyIbiphenyl and potassium carbonate analogously to Example IV, giving a colorless solid (21) of molecular weight 668.54 (C38H32BrF2N03); MS (ESI): 668.1 (MH+). (22): o p- REPLACEMENT SHEET (RULE 26) 32 b) 1 -[4'-(4-{1 -(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2- yl}phenoxymethyl)biphenyl-4-ylmethyl]-4-aza-1 -azoniabicyclo[2.2.2]octane bromide (22): (21) and DABCO are dissolved in toluene and reacted analogously to Example IV, giving the product (22) as a colorless solid of molecular weight 780.76 (C44H44BrF2N303); MS (ESI): 700.3 (MH+).
Example XI 1-(4-Fluorophenyl)-3-[3-(4-f!uorophenyl)-3-hydroxypropyl]-4-(4-{4'-[(2,3,4,5,6-pentahydroxyhexylamine)-methyl]-biphenyl-4-ylmethoxy}-phenyl)-azetidin-2-one (23): (21) and glucamine are dissolved in dimethylformamide and reacted analogously to Example V giving the product (23) as a colorless solid of molecular weight 768.86 20 (C44H46F2N2O8); MS (ESI): 769.3 (MH+).
Example XII 1 -(4-{4-[3-[3-(4-Fluorophenyl)-3-hydroxypropyl]-2-(4-methoxyphenyl)-4-oxoazetidin-1 -yl]-phenoxymethyl}-benzyl)-4-aza-1 -azoniabicyclo[2.2.2]octane bromide (26): » o- REPLACEMENT SHEET (RULE 26) 33 o— f a) 3-[3-(4-Fluorophenyl)-3-hydroxypropyl]-1-(4-hydroxyphenyl)-4-(4-methoxyphenyl)-azetidin-2-one (24): o— f o TX This compound is prepared as described above for 1-(4-aminomethylphenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-methoxyphenyl)-azetidin-2-one (steps a, b, c, and d), except that 4-[(4-methoxybenzylidene)-amino]-phenol is used. This gives 3-[3-(4-fIuorophenyl)-3-hydroxypropyl]-1-(4-hydroxyphenyl)-4-(4-methoxyphenyl)-azetidin-2-one (24) of molecular weight 421.47 (C25H24FNO4); MS (ESI): 422.2 (MH+). b) 1-[4-(4-bromomethylbenzyloxy)-phenyl]-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-methoxyphenyl)-azetidin-2-one (25): o— REPLACEMENT SHEET (RULE 26) 34 3-[3-(4-Fluorophenyl)-3-hydroxypropyl]-1-(4-hydroxyphenyl)-4-(4-methoxyphenyl)-azetidin-2-one is reacted with 1,4-bisbromomethylbenzene and potassium carbonate analogously to Example IV, giving a colorless solid (25) of molecular weight 604.52 (C33H3iBrFN04); MS (ESI): 605.2 (MH+). c) 1-(4-{4-[3-[3-(4-Fluorophenyl)-3-hydroxypropyl]-2-(4-methoxyphenyl)-4- oxoazetidin-1-yl]-phenoxymethyl}-benzyl)-4-aza-1-azoniabicyclo[2.2.2]octane bromide (26): (25) and DABCO are dissolved in toluene and reacted analogously to Example IV, giving the product (26) as a colorless solid of molecular weight 716.70 (C39H43BrFN304); MS (ESI): 636.3 (MH+).
Example XIII 3-[3-(4-Fluorophenyl)-3-hydroxypropyl]-4-(4-methoxyphenyl)-1-(4-{4-[(2,3,4,5,6-pentahydroxyhexylamine)-methyl]-benzyloxy}-phenyl)-azetidin-2-one (27): (25) and glucamine are dissolved in dimethylformamide and reacted analogously to Example V, giving the product (27) as a colorless solid of molecular weight 704.80 (C39H45FN209); MS (ESI): 705.31 (MH+).
REPLACEMENT SHEET (RULE 26) Example XIV 1 -[4-(4-{3-[1 -(4-Fluorophenyl)-2-(4-methoxyphenyl)-4-oxoazetidin-3-yl]-1 -hydroxypropyl}-phenoxymethyl)-benzyl]-4-aza-1-azoniabicyclo[2.2.2]octane bromide (30): o— a) 1-(4-Fluorophenyl)-3-[3-hydroxy-3-(4-hydroxyphenyl)-propyl]-4-(4-methoxyphenyl)-azetidin-2-one (28): This compound is prepared as described above for 1-(4-aminomethylphenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-methoxyphenyl)-azetidin-2-one, except that 3-[5-(4-hydroxyphenyl)-5-hydroxypentanoyl]-4-phenyloxazolidin-2-one and (4-fluorophenyl)-(4-methoxybenzylidene)-amine are used. This gives 1-(4-fluorophenyl)-3-[3-hydroxy-3-(4-hydroxyphenyl)-propyl]-4-(4-methoxyphenyl)-azetidin-2-one (28) of molecular weight 421.47 (C25H24FNO4); MS (ESI): 422.2 (MH+). b) 3-{3-[4-(4-Bromomethylbenzyloxy)-phenyl]-3-hydroxypropyl}-1-(4-fluorophenyl)-4-(4-methoxyphenyl)-azetidin-2-one (29): REPLACEMENT SHEET (RULE 26) 36 o— 1-(4-Fluorophenyl)-3-[3-hydroxy-3-(4-hydroxyphenyl)-propylJ-4-(4-methoxyphenyl)-azetidin-2-one is reacted with 1,4-bisbromomethylbenzene and potassium carbonate 5 analogously to Example IV, giving a colorless solid (29) of molecular weight 604.52 (C33H3iBrFN04); MS (ESI): 605.2 (MH+). c) 1 -[4-(4-{3-[1 -(4-Fluorophenyl)-2-(4-methoxyphenyl)-4-oxoazetidin-3-yl]-1 -10 hydroxypropyl}-phenoxymethyl)-benzyl]-4-aza-1 -azoniabicyclo[2.2.2]octane bromide (30): (29) and DABCO are dissolved in toluene and reacted analogously to Example IV, giving the product (30) as a colorless solid of molecular weight 716.70 15 (C3gH43BrFN304); MS (ESI): 636.3 (MH+).
Example XV 1 -{4-[(4-{1 -(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl}-benzylcarbamoyl)-methyl]-benzyl}-4-aza-1-azoniabicyclo[2.2.2]octane trifluoroacetate (35): REPLACEMENT SHEET (RULE 26) 37 a)- 1-(4-Carboxymethylbenzyl)-4-aza-1-azoniabicyclo[2.2.2]octane bromide (31): ^ At 70°C, 1.0 g of (3-bromomethylphenyl) acetic acid in 5 ml of dimethyl sulfoxide are added to a solution of 1.5 g of 1,4-diazabicyclo[2.2.2]octane in 10 ml of dimethyl sulfoxide. After 1 h, 100 ml of water are added and the mixture is freeze-dried. The residue is digested with acetone. The residue contains the product of molecular 10 weight 261.35 (cation: Ci5H2iN202+); MS (ESI) 261.1 (M+). b) 4-[5-(4-F!uoropheny!)-1-(4-fluorophenylamino)-5-hydroxy-2-(2-oxo-4-phenyIoxazolidine-3-carbonyl)-pentyl]-benzonitrile (32): Under argon, 2.5 g of 3-[5-(4-fluorophenyl)-5-hydroxypentanoylj-4-phenyloxazolidin-2-one are dissolved in 30 ml of dichloromethane, 3.9 g of 4-[(4-fluorophenylimino)-methyl]-benzonitrile are added and the mixture is cooled to -10°C. 6.4 ml of diisopropylethylamine and, over a period of 30 min, 4.05 ml of trimethylsilyl chloride 20 are added to this mixture so that the temperature does not exceed -5°C. The mixture is stirred at this temperature for 1 additional hour and then cooled to -25°C. 0.8 ml of titanium tetrachloride are then added slowly. The dark mixture is stirred at from - 25 to -30°C overnight and then decomposed using 35 ml of a 7 percent strength solution of tartaric acid and then stirred at room temperature for another 25 hour. 15 ml of a 20 percent strength solution of sodium bicarbonate are then added, REPLACEMENT SHEET (RULE 26) 38 and the mixture is again stirred for 1 hour. Following phase separation, the organic phase is washed with 30 ml of water, dried over magnesium sulfate and concentrated to about 10 ml. Following the addition of 2 ml of bistrimethylsilylacetamide, the mixture is heated at reflux for 30 min and then 5 concentrated under reduced pressure. The residue is crystallized using ethyl acetate/heptane. The product is filtered off with suction and dried under reduced pressure. This gives the product of molecular weight 653.81 (C37H37F2N3O4SO; MS (ESI+): 654.3 (M+H+), 582.2 (M+H+ -Si(CH3)3). 1 w , c) {1-(4-FIuorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl}-benzonitrile (33): 2 g of 4-[5-(4-Fluorophenyl)-1-(4-fluorophenylamino)-5-hydroxy-2-(2-oxo-4-phenyl-15 oxazolidine-3-carbonyl)-pentyl]-benzonitrile are dissolved in 20 ml of methyl-tert-butyl ether and, together with 100 mg of tetrabutylammonium fluoride trihydrate and 1.3 ml of bistrimethylsilyl acetamide, heated at 40°C for about 1 h. The reaction is monitored by thin-layer chromatography. After the reaction has ended, 0.2 ml of glacial acetic acid is initially added and the mixture is stirred for 30 min and then 20 concentrated. 20 ml of a mixture of isopropanol/2N sulfuric acid = 10:1 are added to the residue, and the mixture is stirred for 1 hour. Following addition of a spatula tip of solid sodium bicarbonate, the mixture is again concentrated under reduced pressure, the residue is taken up in ethyl acetate and the organic phase is washed with water and dried, and the residue is, after removal of the solvent, purified by column 25 chromatography (Si02, CH2CI2/methanol = 100:1). This gives the product of molecular weight 418.45 (C25H20F2N2O2); MS (DCI+): 419 (M+H+). d) 4-(4-Aminomethylphenyl)-1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-30 hydroxypropyl]-azetidin-2-one (34): REPLACEMENT SHEET (RULE 26) 39 200 mg of {1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3~hydroxypropyl]-4-oxoazetidin-2-yl}-benzonitrile are dissolved in 20 ml of ethanol and, with 0.5 ml of conc. ammonia, hydrogenated over Raney nickel at a hydrogen pressure of 75 bar and at 25°C for 30 hours. The catalyst is filtered off with suction, the mixture is concentrated under 5 • reduced pressure and the residue is purified by column filtration (Si02, CH2Cl2/methanol/conc. NH3 = 100:10:1). This gives the product of molecular weight 422.5 (C25H22F2N2O2); MS (DCI+): 423 (M+H+), 405 (M+H+- H20).
I e) 1 -{4-[(4-{1 -(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl}-benzylcarbamoyl)-methyl]-benzyl}-4-aza-1-azonia-bicyclo[2.2.2]octane; trifluoroacetate (35): A solution of 70 mg 4-(4-aminomethylphenyl)-1-(4-fluorophenyl)-3-[3-(4-15 fluorophenyl)-3-hydroxypropyl]-azetidin-2-one, and 23 pi of triethylamine in 0.5 ml of dimethylformamide is added to a solution of 84 mg of 1-(4-carboxymethylbenzyl)-4-aza-1-azoniabicyclo[2.2.2]octane bromide, 64 pi of diisopropylcarbodiimide and 56 mg of hydroxybenzotriazole in 2 ml of dimethylformamide, and the mixture is stirred at room temperature for 12 h. The reaction solution is concentrated and 20 separated by HPLC (Knauer Eurospher-100-10-C18, water (0.1% trifluoroacetic acid)/acetonitrile (0.1% trifluoroacetic acid) = 80/20 -> 10/90). This gives the product of molecular weight 665.81 (cation: C40H43F2N4O3); MS (ESI) 665.33 (M+).
Example XVI 1-{4-[(4-{1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl}-benzylcarbamoyl)-methyI]-benzyl}-1-azoniabicyclo[2.2.2]octane trifluoroacetate (37): REPLACEMENT SHEET (RULE 26) 40 F © a) 1-(4-Carboxymethylbenzyl)-1-azoniabicyclo[2.2.2]octane bromide (36): The synthesis is carried out analogously to Example XVa) starting with 1.67 g of 1-™ azabicyclo[2.2.2]octane. This gives the product of molecular weight 260.36 (cation: C16H22Ni02+); MS (ESI) 260.1 (M+). b) 1 -{4-[(4-{1 -(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl}-benzylcarbamoyl)-methyl]-benzyl}-1 -azoniabicyclo[2.2.2]octane trifluoroacetate (37): The synthesis is carried out analogously to Example XVe) starting with 70 mg of 4-15 (4-aminomethylphenyl)-1 -(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-a azetidin-2-one and 85 mg of 1-(4-carboxymethylbenzyl)-1-azoniabicyclo[2.2.2]octane ^ bromide. This gives the product of molecular weight 664.82 (cation: C4iH44F2N303+); MS (ESI) 664.33 (M+).
Example XVII 1-{4-[(4-{1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl}-benzylcarbamoyl)-methyl]-benzyl}-1,4-dimethylpiperazin-1 -ium trifluoroacetate (39): REPLACEMENT SHEET (RULE 26) 41 a) 1-(4-Carboxymethylbenzyl)-1,4-dimethylpiperazin-1-ium bromide (38): The synthesis is carried out analogously to Example XVa) starting with 1.02 ml of 1,4-dimethylpiperazine. This gives the product of molecular weight 263.36 (cation: Ci5H23N202+); MS (ESI) 263.1 (M+). b) 1 -{4-[(4-{1 -(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl}-benzylcarbamoyl)-methyl]-benzyl}-1,4-dimethyl-piperazin-1-ium trifluoroacetate (39): The synthesis is carried out analogously to Example XVe) starting with 70 mg of 4-(4-aminomethylphenyl)-1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-azetidin-2-one and 86 mg of 1-(4-carboxymethylbenzyl)-1,4-dimethylpiperazin-1-ium bromide. This gives the product of molecular weight 667.82 (cation: C^hUsF^CV"); MS (ESI) 667.34 (M+).
Example XVIII 4-{4-[(4-{1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl}-benzylcarbamoyl)-methyl]-benzyl}-4-methylmorpholin-4-ium trifluoroacetate (41): REPLACEMENT SHEET (RULE 26) 42 a) 4-(4-Carboxymethylbenzyl)-4-methylmorpholin-4-ium bromide (40): The synthesis is carried out analogously to Example XVa) starting with 1.65 ml of N-methylmorpholine. This gives the product of molecular weight 250.32_(cation: Ci4H2ONI03+); MS (ESI) 250.1 (M+). b) 4-{4-[(4-{1 -(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4- oxoazetidin-2-yl}-benzylcarbamoyl)-methyl]-benzyl}-4-methylmorpholin-4-ium trifluoroacetate (41): The synthesis is carried out analogously to Example XVe) starting 70 mg of 4-(4-aminomethylphenyl)-1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-azetidin-2-one and 82 mg of 4-(4-carboxymethylbenzyl)-4-methylmorpholin-4-ium bromide. This gives the product of molecular weight 654.78 (cation: C39H42F2N304+); MS (ESI) 654.31 (M+).
% Example XIX 1-{4-[(4-{1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-25 yl}-benzylcarbamoyl)-methyl]-benzyl}-1,4,7-trimethyl-[1,4,7]triazonan-1 -ium trifluoroacetate (43): REPLACEMENT SHEET (RULE 26) -v 43 a) 1,4,7-Trimethyl-1 -[4-(2-oxopropyl)-benzyl]-[1,4,7]triazonan-1 -ium bromide (42): The synthesis is carried out analogously to Example XVa) starting with 500 mg of 1,4,7-trimethyl-[1,4,7]triazonane. This gives the product of molecular weight 321.47 10 (cation: C18H31N302+); MS (ESI) 321.2 (M+). b) 1 -{4-[(4-{1 -(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl}-benzylcarbamoyl)-methyl]-benzyl}-1,4,7-trimethyl-w [1,4,7]triazonan-1 -ium trifluoroacetate (43): The synthesis is carried out analogously to Example XVe) starting 70 mg of 4-(4-aminomethylphenyl)-1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-azetidin-2-one and 200 mg of 1,4,7-trimethyl-1-[4-(2-oxopropyl)-benzyl]-20 [1,4,7]triazonan-1 -ium bromide. This gives the product of molecular weight 724.92 (cation: C40H45F2N4CV); MS (ESI) 724.40 (M+).
REPLACEMENT SHEET (RULE 26) 44 Example XX 1-[4-({4-[3-(3-Hydroxy-3-phenylpropyl)-2-oxo-4-phenylazetidin-1-yl]-benzylcarbamoyl}-methyl)-benzyl]-4-aza-1-azoniabicyclo[2.2.2]octane trifluoroacetate (44): The synthesis is carried out analogously to Example XVe) starting 60 mg of 1-(4-aminomethylphenyl)-3-(3-hydroxy-3-phenylpropyl)-4-phenylazetidin-2-one (8) and 82 10 mg of 1 -(4-carboxymethylbenzyl)-4-aza-1 -azoniabicyclo[2.2.2]octane bromide. This gives the product of molecular weight 629.83_(cation: C4oH45F2N403+); MS (ESI) 629.35 (M+).
Example XXI N-(4-{1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl}-benzyl^-^-^SAS^-pentahydroxyhexylamino^methyri-phenylJ-acetamide (46): REPLACEMENT SHEET (RULE 26) 45 a) {4-[(2,3,4,5,6-Pentahydroxyhexylamino)-methyl]-phenyl}-acetic acid (45): w The synthesis is carried out analogously to Example XVa) starting with 989 mg of 6-aminohexane-1,2,3,4,5-pentaol. This gives the product of molecular weight 329.35 (C15H23N1O7); MS (ESI) 330.2 (M + H+). b) N-(4-{1 -(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl}-benzyl)-2-{4-[(2,3,4,5>6-pentahydroxyhexylamino)-methyl]-phenyl}-acetamide (46): The synthesis is carried out analogously to Example XVe) starting 70 mg of 4-(4-aminomethylphenyl)-1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-azetidin-2-one and 110 mg of {4-[(2,3,4I5,6-pentahydroxyhexylamino)-methyl]-phenyl}-acetic acid. This gives the product of molecular weight 733.82 (C40H45F2N3CV); MS (ESI) 734.32 (M + H+).
Example XXII N-(4-{1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl}-25 benzyl)-2-(4-{[methyl-(2I3,4,5,6-pentahydroxyhexyl)-amino]-methyl}-phenyl)-acetamide (48): REPLACEMENT SHEET (RULE 26) 46 # a) (4-{[Methyl-(2,3,4,5,6-pentahydroxyhexyl)-amino]-methyl}-phenyl)-acetic acid (47): The synthesis is carried out analogously to Example XVa) starting with 1.06 g of 6-methylaminohexane-1,2,3,4,5-pentaol. This gives the product of molecular weight 10 343.38_(Ci6H25NI07); MS (ESI) 344.2 (M + H+). b) N-(4-{1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl}-benzyl)-2-(4-{[methyl-(2,3,4,5,6-pentahydroxyhexyl)-amino]-methyl}-15 phenyl)-acetamide (48): % The synthesis is carried out analogously to Example XVe) starting 70 mg of 4-(4-aminomethylphenyl)-1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-azetidin-2-one and 114 mg of (4-{[methyl-(2,3,4,5,6-pentahydroxyhexyl)-amino]-20 methyl}-phenyl)-acetic acid. This gives the product of molecular weight 747.84 (C4iH47F2N308+); MS (ESI) 748.35 (M + H+).
REPLACEMENT SHEET (RULE 26) 47 Table 1: Compounds of the formula I REPLACEMENT SHEET (RULE 26) 48 Ex.
R1.R2 R3, R4 R5, R6 Salz Molecular weight of the free base or acid (calculated) Molecular weight (found) XXIII para ,H para-F, H para-F.H cr 651.78 651.31 (M+) XXIV . H Psra nt\ w para-F, H para-F.H cf3c 00' 651.78 651.31 (M+) XXV VOf .H r—H v—' qh para ' para-F, H para-F,H 567.64 577.25 (MH+) XXVI >(XK-" para / H para-F, H para-F, H 662.69 663.22 (MH+) XXVII para-0-CH3, H NH OH OH pert ^ para-F.H cf3c OOH 745.85 746.34 (MH+) XXVIII para-0-CH3, H ,H NH C*. OK OH pars para-F.H cf3c OOH 759.88 760.35 (MH+) XXIX KM OH ON para-F, H para-F.H 739.82 740.33 (MH+) XXX Vv /~H °v_ b -© para-F, H para-F.H cf3c 00" 695.84 659.34 (M+) XXXI r>sj& .h para-F, H para-F, H cf3c 00" 709.86 709.35 (M+) XXXII O^OH para ' J] f O OH para-F, H para-F, H 614.60 597.18 (MH*-H20) REPLACEMENT SHEET (RULE 26) 49 XXXIII Y™1 r"yU\.#>° para ' (] J 0 OH para-F, H para-F.H 620.65 621.24 (MH+) XXXIV °hD4"oh ,h para-F, H para-F, H 606.65 607.32 (MH+) XXXV pwa /"~8 para-F, H para-F, H CF3C 00" 681.33 681,5 (M+) XXXVI para-0-CH3, H P«a .H o para-F.H cr 755.92 755.36 (M+) XXXVII para-0-CH3, H <»ra TXX/ ■« /-OH H, H 615.71 616.21 (MH+) XXXVIII para-F, H para-F.H CF3C OOH 554.65 555.20 (MH+) XXXIX 4or ■" NH N ' 0 ( para para-F, H para-F.H 606.65 607.39 (MH*) XL para-0-CH3, H X °v. zz i para-F, H cr 775.95 775.40 (M+) XLI para-0-CH3, H -oyCAV" para-F, H cr 699.85 699.33 (M+) XLII para-0-CH3, H para-F.H HCI 651.74 652.38 (MH+) XLI II para-0-CH3, H para-F, H Br 860.51 860.6 (M+) XLIV para-0-CH3, H -^V^C,H 0 para-F, H 595.67 596.38 (MH+) REPLACEMENT SHEET (RULE 26) 50 XLV para-0-CH3, H nh para-F.H CF3C OOH 652.73 653.37 (MH+) XLVI para-0-CH3, H 0 para-F, H 618.68 617.33 (M-H*; measured in negative mode XLV1I para-0-CH3, H -OL0 IX-T 4. para-F, H 730.81 731.41 (MH+) XLVI II para-0-CH3, H , h ho para-F,H 672.76 655.28 (MH+-H20) IL para-0-CH3, H 0 ^vO^0H -h 0 para-F,H 658.73 659.27 (MH+) L para-0-CH3l H para y\J rs ,h / vo ho para-F.H 710.78 693.25 (MH+-H20) LI para-0-CH3, H para-F, H cr 663.82 663.28 (M+) Lll para-0-CH3l H 0 para-F, H 588.68 589.34 (MH+) LI 11 para-0-CH3, H 0 para-F, H 674.73 657.35 (MH+-H20) LIV para-0-CH3, H para ^ T XX/ •" cT0H para-F, H 633.70 615.70 (M+-HzO) REPLACEMENT SHEET (RULE 26) 51 LV para-0-CH3, H ~^rtxp •» para-F, H Br 666.72 666.33 (M+) LVI ""^rolp •» para-F, H paraph H Br 654.68 654.31 (M+) LVII Pa,aV-N ^ ■» para-F, H para-F, H r 687.35 687.4 (M+) LVI 11 para "/° ,H /-OH para-F, H para-F,H 571.65 572.4 (MH+) LIX \'0H ^ x jcx° ■* para n"^-^ H H para-F, H para-F, H 621.66 622.33 (MH+) LX para-0-CH3, H ft .m para-F, H 801.98 784.21 (M+-H20) LXI para-0-CH3, H 4 o h h para-F, H 775.90 758.18 (M+-H20) LXII para-0-CH3, H ocjao « n fa, para-F,H 882.04 883.49 (MH+) REPLACEMENT SHEET (RULE 26) 52 Using the method described below, the activity of the compounds of the formula I according to the invention was examined: Effect on cholesterol absorption + 3H-taurocholic acid excretion using fecal 5 excrement of mice, rats or hamsters NMRI mice, Wistar rats, or Golden Syrian hamsters (in groups of n=4-6) are kept in metabolic cages, where they are fed with a standard diet (Altromin, Lage (Lippe)). The afternoon prior to the administration of the radioactive tracers (14C-cholesterol), ^ the feed is removed and the animals are adapted to grates.
Additionally, the animals are labeled s.c. with 3H-TCA (taurocholic acid) (for example 1 pCi/mouse up to 5 pCi/rat) 24 hours prior to the peroral administration of the test meal (14C-cholesterol in Intralipid® 20, Pharmacia-Upjohn).
Cholesterol absorption test: 0.25 ml/mouse Intralipid ® 20 (Pharmacia-Upjohn) ((spiked with 0.25 pCi of 14C-cholesterol in 0.1 mg of cholesterol) is administered perorally by gavage.
Test substances are prepared separately in 0.5% methylcellulose (Sigma)/5% Solutol (BASF, Ludwigshafen) or a suitable vehicle.
The administration volume of the test substance is 0.5 ml/mouse. The test substance is administered immediately prior to the test meal (Intralipid labeled with 14C-cholesterol) (cholesterol absorption test).
The feces are collected over a period of 24 h: fecal elimination of 14C-cholesterol and 3H-taurocholic acid (TCA) is determined after 24 hours.
The livers are removed and homogenized, and aliquots are incinerated in an oximate 30 (Model 307, Packard) to determine the amount of 14C-cholesterol which had been taken up/absorbed.
REPLACEMENT SHEET (RULE 26) 53 Evaluation: Feces samples: The total weight is determined, the sample is made up with water to a defined 5 • volume and then homogenized, and an aliquot is evaporated to dryness and incinerated in an oximate (Model 307 from Packard for the incineration of radioactively labeled samples): the amount of radioactive 3H-H20 and 14C-C02 is extrapolated to the amount of 3H-taurocholic acid and 14C-cholesterol, respectively, that is excreted (dual isotope technique). The ED2oo values as dose from a dose-effect curve are interpolated as those doses at which the excretion of TCA or V cholesterol is doubled, based on a control group treated at the same time.
Liver samples: The amount of 14C-cholesterol taken up by the liver is based on the administered 15 dose. The ED50 values are interpolated from a dose-effect curve as the dose at which the uptake of 14C-cholesterol by the liver is halved (50%), based on a control group.
The ED50 values below demonstrate the activity of the compounds of the formula I 20 according to the invention % Example No.
ED5o (liver) [mg/mouse] VII VIII VI V IX IV II <0.1 < 1.0 <0.1 <0.1 0.3 <1.0 < 1.0 <0.1 REPLACEMENT SHEET (RULE 26) i 54 XV < 1.0 XXIII 0.3 XXV 0.3 XXVI 0.1 XXVII 0.3 XXIX 0.3 XXXI 0.3 XXXVI 0.03 XXXVII 0.1 XXXVIII 0.1 XLI 0.03 XLIII 0.3 XL IV 0.3 XLVI 0.3 XLVI 11 0.03 L 0.1 Lll 0.3 Llll 0.03 As can be seen from the table, the compounds of the formula I have very good cholesterol-lowering action.
Bioabsorption: The bioabsorption of the compounds of the formula I was examined using the Caco cell model (A.R. Hilgers et al., Caco-2 cell monolayers as a model for drug transport across the intestinal mucosa, Pharm. Res. 1990, 7, 902).
From the measured data, it can be seen that the bioabsorption of the compounds of 30 the formula I according to the invention is considerably lower than that of the compounds described in the prior art (reference structure): REPLACEMENT SHEET (RULE 26)

Claims (22)

1. 55 Reference structure: Ezetimibe REPLACEMENT SHEET (RULE 26) WO 2004/000804 56 PCT/EP2003/005815 Patent claims: A compound of the formula I, 0 V^R3 in which R1, R2, R3, R4, R5, R6 independently of one another are (C1-C30)- alkylene-(LAG)n, where n = 1 - 5 and where one or more carbon atoms of the alkylene radical are replaced by aryl or heteroaryl radicals substituted up to three times by R7, or by (C3-C-io)-cycloalkyl or heterocycloalkyl radicals substituted up to four times by R7 and where one or more carbon atoms of the alkylene radical may be replaced by -S(0)n-, where n = 0 - 2, -0-, -(C=0)-, -(C=S)-, -CH=CH-, -CEC-, -N((CrC6)-alkyl)-, -N(phenyl), -N((C-i-C6)-alkyl-phenyl)-, -N(CO~ (CH2)i-io-COOH)- or-NH-; H, F, CI, Br, I, CF3, N02, N3, CN, COOH, COO(CrC6)-alkyl, CONH2, CONH(CrC6)-a!kyl, CON[(CrC6)-alkyl]2, (CrC6)-alkyl, (C2-C6)-alkenyl, REPLACEMENT SHEET (RULE 26) 57 (C2-C6)-alkynyl, 0-(Ci-C6)-alkyl, where one, more or all hydrogens in the alkyl radicals may be replaced by fluorine; S02-NH2, SOjzNHfCi-CeJ-alkyl. S02N[(CrC6)-alkyl]2 , S-(CrC6)-alkyl, S-(CH2)n-phenyl, SO-(CrC6)-alkyl, SO-(CH2)n-phenyl, S02-(Ci-C6)-alkyl, 5 , S02-(CH2)n-phenyl, where n = 0 - 6 and the phenyl radical may be substituted up to two times by F, CI, Br, OH, CF3, N02, CN, OCF3, O-(CrC6)-alkyl, (CrC6)-alkyl, NH2; NH2, NH-(Ci-C6)-alkyl, N((CrC6)-alkyI)2, NH(CrC7)-acyl, phenyl, O-(CH2)n-phenyl, where n = 0 - 6, where the phenyl ring may be mono- to 10 trisubstituted by F, CI, Br, I, OH, CF3, N02, CN, OCF3, 0-(Ci-C6)-alkyl, £ (CrC6)-alkyl, NH2, NH(Ci-C6)-alkyl, N((CrC6)-alkyl)2, S02-CH3, COOH, COO-(Ci-C6)-alkyl, CONH2; R7 is F, CI, Br, I, CF3, N02, N3, CN, COOH, COO(CrC6)-alkyl, CONH2, 15 CONH(CrC6)-alkyl, CON[(CrC6)-alkyl]2, (Ci-C6)-alkyl, (C2-C6)-alkenyl, (C2-C6)-aIkynyl, 0-(Ci-C6)-alkyl, where one, more or all hydrogens in the alkyl radicals may be replaced by fluorine; P03H2, SO3H, S02-NH2, S02NH(Ci-C6)-alkyl, S02N[(CrC6)-alkyl]2 , S-(Ci-C6)-alkyl, S-(CH2)n-phenyl, SO-(C-i-C6)-alkyl, SO-(CH2)n-phenyl, 20 S02-(Ci-C6)-alkyl, S02-(CH2)n-phenyl, where n = 0 - 6 and the phenyl radical may be substituted up to two times by F, CI, Br, OH, CF3, N02, V CN, OCF3i 0-(CrC6)-alkyl, (CrC6)-alkyl, NH2; C(NH)(NH2), NH2, NH-(Ci-C6)-alkyl, N^CrCeJ-alkyOs, NH(CrC7)-acyl, phenyl, 0-(CH2)n-phenyl, where n = 0 - 6, where the phenyl ring may be 25 mono- to trisubstituted by F, CI, Br, I, OH, CF3, N02, CN, OCF3, 0-(Cr C6)-alkyl, (Ci-C6)-alkyl, NH2, NH(CrC6)-alkyl, N((CrC6)-alkyl)2, S02-CH3, COOH, COO-tCrCeJ-alkyl, CONH2; (LAG)n is a sugar residue, disugar residue, trisugar residue, tetrasugar residue; 30 a sugar acid, an amino sugar; REPLACEMENT SHEET (RULE 26) 58 an amino acid residue, an oligopeptide residue comprising 2 to 9 amino acids; an acyclic, mono-, di- or tricyclic trialkylammonium radical, an acyclic mono-, di- or tricyclic trialkylammoniumalkyl radical, -0-(S02)-OH; -(CH2)O.IO-S03H;-(CH2)O-IO-P(0)(OH)2,-(CH2)0-I0-O-P(O)(OH)2, -(CH2)O-IO-COOH, -(CH2)O-IO-C(=NH)(NH2); -(CH2)O-io-C(=NH)(NHOH); -NR8-C(=NR9)(NR10R11); where n = 1 - 5 and R8, R9, R10 and R11 independently of one another may be H, (CrC6)-alkyl, phenyl, (C-i-Ce)-alkyl-phenyl, (C3-C8)-cycloalkyl), and where in each case at least one of the radicals R1 to R6 must have the meaning (CrC3o)-alkylene-(LAG)n, where n = 1 - 5 and one or more carbon atoms of the alkylene radical are replaced by up to trisubstituted aryl or heteroaryl radicals or by up to tetrasubstituted (C3-C-|0)-cycloalkyl or heterocycloalkyl radicals and may additionally be replaced by -S(0)n-, where n = 0 - 2, -0-, -(C=0)-, -(C=S)-, -CH=CH-, -CEC-, -N((CrC6)-alkyl)-, -N(phenyl)-, -N((Ci-C6)-alkyl-phenyl)-, -N(CO-(CH2)i-io-COOH)- or -NH-; and its pharmaceutically acceptable salts.
2. A compound of the formula I as claimed in claim 1, wherein R2, R4, R5, R6 independently of one another are H, F, CI, Br, I, CF3, N02, N3, CN, COOH, COO(C-i-C6)-alkyl, CONH2, CONH(CrC6)-alkyl, CON[(Ci-C6)-alkyl]2> (C-i-C6)-alkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, O-(C-i-C6)-aIkyl, where one, more or all hydrogens in the alkyl radicals may be replaced by fluorine; S02-NH2, S02NH(C1-C6)-alkyl, S02N[(CrC6)-alkyl]2, S-(CrC6)-alkyl, S-(CH2)n-phenyl, SO-(CrC6)-alkyl, SO-(CH2)n-phenyl, S02-(Ci-C6)-alkyl, S02-(CH2)n-phenyl, where n = 0 - 6 and the phenyl radical may be REPLACEMENT SHEET (RULE 26) substituted up to two times by F, CI, Br, OH, CF3, NO2, CN, OCF3, O-(Ci-C6)-alky|, (Ci-C6)-alkyl, NH2; NH2, NH-(CrC6)-alkyl, NKCi-CeJ-alkylk, NH(CrC7)-acyl, phenyl, O-(CH2)n-phenyl, where n = 0 - 6, where the phenyl ring may be mono- to trisubstituted by F, CI, Br, I, OH, CF3, N02, CN, OCF3, 0-(Ci-C6)-alkyl, (Ci-C6)-alkyl, NH2, NH(CrC6)-alkyl, N((Ci-C6)-alkyl)2, S02-CH3, COOH, COO-(CrC6)-alkyl, CONH2; independently of one another are (Ci-C3o)-alkylene-(LAG), where one or more carbon atoms of the alkylene radical are replaced by aryl or heteroaryl radicals substituted up to three times by R7, or by (C3-C10)-cycloalkyl or heterocycloalkyl radicals substituted up to three times by R7 and where one or more carbon atoms of the alkylene radical may be replaced by -S(0)n-, where n = 0 - 2, -0-, -(C=0)-, -N(CH3)-, -N(phenyl)-, -N(CO-(CH2)i.10-COOH)- or-NH-, H, F, CI, Br, I, CF3, N02, N3, CN, COOH, COO(Ci-C6)-alkyl, CONH2, CONH(Ci-C6)-alkyl, CON[(Ci-C6)-alkyl]2, (Ci-C6)-alkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, 0-(CrC6)-alkyl, where one, more or all hydrogens in the alkyl radicals may be replaced by fluorine; S02-NH2, S02NH(CrC6)-alkyl, S02N[(CrC6)-alkyl]2 , S-(Ci-C6)-alkyl, S-(CH2)n-phenyl, SO-(Ci-C6)-alkyl, SO-(CH2)n-phenyl, S02-(CrC6)-alkyl, S02-(CH2)n-phenyl, where n = 0 - 6 and the phenyl radical may be substituted up to two times by F, CI, Br, OH, CF3, N02, CN, OCF3, O-(CrC6)-alkyl, (CrC6)-alkyl, NH2; NH2, NH-(CrC6)-alkyl, N((C1-C6)-alkyl)2, NH(C1-Cr)-acyl, phenyl, 0-(CH2)n-phenyl, where n = 0 - 6, where the phenyl ring may be mono- to trisubstituted by F, CI, Br, I, OH, CF3, N02, CN, OCF3, 0-(Ci-C6)-alkyl, (CrC6)-alkyl, NH2, NH(CrC6)-alkyl, N((CrC6)-alkyl)2, S02-CH3, COOH, COO-(Ci-C6)-alkyl, CONH2; REPLACEMENT SHEET (RULE 26) R7 is F, CI, Br, I, CF3, N02, N3, CN, COOH, COO(Ci-C6)-alkyl, CONH2, CONH(Ci-C6)-alkyl, CON[(Ci-C6)-alkyl]2, (CrC6)-alkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, 0-(CrC6)-alkyl, where one, more or all hydrogens in the alkyl radicals may be replaced by fluorine; P03H2, S03H, S02-NH2, S02NH(CrC6)-alkyl, S02N[(Ci-C6)-alkyl]2 , S-(Ci-C6)-alkyl, S-(CH2)n-phenyl, SO-(CrC6)-alkyl, SO-(CH2)n-phenyl, S02-(CrC6)-alkyl, S02-(CH2)n-phenyl, where n = 0 - 6 and where the phenyl radical may be substituted up to two times by F, CI, Br, OH, CF3, N02, CN, OCF3, 0-(Ci-C6)-alkyl, (CrCeJ-alkyl, NH2; C(NH)(NH2), NH2, NH-(CrC6)-alkyl, N((CrC6)-alkyl)2, NH(CrC7)-acyl, phenyl, 0-(CH2)n-phenyl, where n = 0 - 6, where the phenyl ring may be mono- to trisubstituted by F, CI, Br, I, OH, CF3, N02, CN, OCF3, 0-(Cr C6)-alkyl, (CrC6)-alkyl, NH2, NH(C-,-C6)-alkyl, N((CrC6)-alkyl)2, S02-CH3, COOH, COO-(CrC6)-alkyl, CONH2; (LAG) is a sugar residue, disugar residue, trisugar residue, tetrasugar residue; a sugar acid, an amino sugar; an amino acid residue, an oligopeptide residue comprising 2 to 9 amino acids; an acyclic, mono-, di- or tricyclic trialkylammonium radical, an acyclic mono-, di- or tricyclic trialkylammoniumalkyl radical, -0-(S02)-0H; -(CH2)o-io-S03H; -(CH2)o-io-P(0)(OH)2, -(CH2)0-i0-O-P(O)(OH)2, -(CH2)o-io-COOH, -(CH2)o-io-C(=NH)(NH2); -(CH2)0-i0-C(=NH)(NHOH); -NR8-C(=NR9)(NR10R11); where n = 1 - 5 and R8, R9, R10 and R11 independently of one another may be H, (CrC6)-alkyl, phenyl, (C-i-C6)-alkyl-phenyl, (C3-C8)-cycloalkyl), and where in each case at least one of the radicals R1 or R3 must have the meaning (CrC3o)-alkylene-(LAG), where one or more carbon atoms of the alkylene radical are replaced by up to trisubstituted aryl or heteroaryl radicals or by up to trisubstituted (C3-C-io)-cycloalkyl or heterocycloalkyl radicals and may additionally be replaced by REPLACEMENT SHEET (RULE 26) -S(0)n-, where n = 0 - 2, -0-, -(C=0)-, -N(CH3)-, -N(phenyl)-, -N(CO-(CH2)i-io- COOH)- or -NH-; and its physiologically acceptable salts.
3. A comppund of the formula I as claimed in claim 1 or 2, wherein R2, R4, R5, R6 independently of one another are H, F, CI, Br, I, CF3, N02, N3, CN, COOH, COO(Ci-C6)-alkyl, CONH2, CONH(CrC6)-alkyl, CON[(Ci-C6)-alkyl]2, (CrC6)-alkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, O-(CrC6)-alkyl, where one, more or all hydrogens in the alkyl radicals may be replaced by fluorine; S02-NH2, S02NH(CrC6)-alkyl, S02N[(CrC6)-alkyl]2 , S-(Ci-C6)-alkyl, S-(CH2)n-phenyl, SO-(C-i-C6)-alkyl, SO-(CH2)n-phenyl, S02-(CrC6)-alkyl, S02-(CH2)n-phenyl, where n = 0 - 6 and the phenyl radical may be substituted up to two times by F, CI, Br, OH, CF3, N02, CN, OCF3, O-(CrC6)-alkyl, (CrCeJ-alkyl, NH2; NH2, NH-(CrC6)-alkyl, NaCrCeJ-alkylk, NH(CrC7)-acyl, phenyl, O-(CH2)n-phenyl, where n = 0 - 6, where the phenyl ring may be mono- to trisubstituted by F, CI, Br, I, OH, CF3, N02, CN, OCF3, 0-(CrC6)-alkyl, (CrC6)-alkyl, NH2, NH(Ci-C6)-alkyl, N((CrC6)-alkyl)2, S02-CH3, COOH, COO-(Ci-C6)-alkyl, CONH2; R1, R3 independently of one another are -(CH2)o-rNH-(C=0) o-i-(Co-C25)- alkylene-(C=O)0.rN(R13)0-i-(LAG) or -(CH2)0-i-(C=O) 0-rNH-(C0-C25)-alkylene-(C=0)o-i-N(R13)o-r(LAG); where one or more carbon atoms of the alkylene radical are replaced by aryl or heteroaryl radicals substituted up to three times by R7, or by (C3-Cio)-cycloalkyl or heterocycloalkyl radicals substituted up to three times by R7 and where one or more carbon atoms of the alkylene radical may be replaced by oxygen atoms; REPLACEMENT SHEET (RULE 26) H, F, CI, Br, I, CF3, N02, N3i CN, COOH, COO(CrC6)-alkyl, CONH2, CONH(Ci-C6)-alkyl, CON[(CrC6)-alkyl]2, (CrC6)-alkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, 0-(CrC6)-alkyl, where one, more or all hydrogens in the alkyl radicals may be replaced by fluorine; S02-NH2, S02NH(Ci-C6)-alkyl, S02N[(CrC6)-alkyl]2 , S-(CrC6)-alkyl, S-(CH2)n-phenyl, SO-(CrC6)-alkyl, SO-(CH2)n-phenyl, S02-(CrC6)-alkyl, S02-(CH2)n-phenyl, where n = 0 - 6 and the phenyl radical may be substituted up to two times by F, CI, Br, OH, CF3, N02, CN, OCF3, O-(CrC6)-alkyl, (CrC6)-alkyl, NH2; NH2, NH-(Ci-C6)-alkyl, N((C-i-C6)-alkyl)2, NH(Ci-C7)-acyl, phenyl, O-(CH2)n-phenyl, where n = 0 - 6, the phenyl ring may be mono- to trisubstituted by F, CI, Br, I, OH, CF3, N02, CN, OCF3, 0-(CrC6)-alkyl, (CrC6)-alkyl, NH2, NH(C.,-C6)-alkyl, N((CrC6)-alkyl)2, S02-CH3, COOH, COO-(CrC6)-alkyI, CONH2; is F, CI, Br, I, CF3, N02, N3, CN, COOH, COO(CrC6)-alkyl, CONH2, CONH(CrC6)-alkyl, CON[(Ci-C6)-alkyl]2, (CrC6)-alkyl, (C2-C6)-alkenyl, (C2-Ce)-alkynyl, 0-(CrCe)-alkyl, where one, more or all hydrogens in the alkyl radicals may be replaced by fluorine; P03H2, S03H, S02-NH2, S02NH(Ci-C6)-alkyl, S02N[(CrC6)-alkyl]2, S-(CrC6)-alkyl, S-(CH2)n-phenyl, SO-(CrC6)-alkyl, SO-(CH2)n-phenyl, S02-(CrC6)-alkyl, S02-(CH2)n-phenyl, where n = 0 - 6 and the phenyl radical may be substituted up to two times by F, CI, Br, OH, CF3, N02, CN, OCF3, 0-(CrC6)-alkyl, (Ci-C6)-alkyl, NH2; C(NH)(NH2), NH2, NH-(CrC6)-alkyl, N((CrC6)-alkyl)2, NH(CrC7)-acyl, phenyl, 0-(CH2)n-phenyl, where n = 0 - 6, where the phenyl ring may be mono- to trisubstituted by F, CI, Br, I, OH, CF3, N02, CN, OCF3, 0-(Cr C6)-alkyl, (C-i-CeJ-alkyl, NH2, NH(Ci-C6)-alkyl, N((CrC6)-alkyl)2, S02-CH3, COOH, COO-(CrC6)-alkyl, CONH2; REPLACEMENT SHEET (RULE 26) 63 i 15 (LAG)n is a sugar residue, disugar residue, trisugar residue, tetrasugar residue; a sugar acid, an amino sugar; an amino acid residue, an oligopeptide residue comprising 2 to 9 amino acids; an acyclic, mono-, di- or tricyclic trialkylammonium radical, an acyclic mono-, di- or tricyclic trialkylammoniumalkyl radical, -0-(S02)-0H; -(CH2)0-IO-S03H; -(CH2)O-IO-P(0)(OH)2, -(CH2)0-I0-O-P(O)(OH)2, -(CH2)O-io-COOH, -(CH2)O_IO~C(=NH)(NH2); -(CH2)O-IO-C(=NH)(NHOH); -NR8-C(=NR9)(NR10R11); where n = 1 - 5 and R8, R9, R10 and R11 independently of one another may be H, (CrC6)-alkyl, phenyl, (C-i-Ce)-alkyl-phenyl, (C3-C8)-cycloalkyl), R13 isHorCH3; and where in each case at least one of the radicals R1 or R3 must have the meaning -(CH2)0-i-NH-(C=O) o-i-(Co-C25)-alkylene-(C=0)o-i-N(R13)0-i-(LAG) or -(CH2)0-i-(C=0)o.i-NH-(Co-C25)-alkylene-(C=0)o-i-N(R13)o.i-(LAG) and one or more carbon atoms of the alkylene radical are replaced by up to trisubstituted aryl or heteroaryl 20 radicals or by up to trisubstituted (C3-C10)-cycloalkyl or heterocycloalkyl radicals and may additionally be replaced by -S(0)n-, where n = 0 - 2, -0-, -(C=0)-, -N(CH3)-, -N(phenyl)- or -NH-; and its physiologically acceptable salts. 25
4. A compound of the formula I as claimed in one or more of claims 1 to 3, wherein LAG is a monosugar residue, an acyclic mono-, di- or tricyclic trialkylammoniumalkyl radical, a sulfonic acid or a carboxylic acid, and its pharmaceutically acceptable salts. 30
5. A medicament comprising one or more compounds as claimed in one or more REPLACEMENT SHEET (RULE 26) 64 of claims 1 to 4.
6. A medicament comprising one or more compounds as claimed in one or more of claims 1 to 4 and at least one further active compound. 5
7. The medicament as claimed in claim 6, comprising, as further active compound, one or more compounds which normalize lipid metabolism.
8. The medicament as claimed in claim 6 or 7, which comprises, as further § active compound, one or more antidiabetics, hypoglycemically active compounds, HMGCoA reductase inhibitors, cholesterol absorption inhibitors, PPAR gamma agonists, PPAR alpha agonists, PPAR alpha/gamma agonists, fibrates, MTP inhibitors, bile acid absorption inhibitors, CETP inhibitors, polymeric bile acid adsorbers, LDL receptor inducers, ACAT 15 inhibitors, antioxidants, lipoprotein lipase inhibitors, ATP citrate lyase inhibitors, squalene synthetase inhibitors, lipoprotein(a) antagonists, lipase inhibitors, insulins, sulfonylureas, biguanides, meglitinides, thiazolidinediones, a-glucosidase inhibitors, active compounds which act on the ATP-dependent potassium channel of the beta cells, CART agonists, NPY agonists, MC4 agonists, orexin agonists, H3 agonists, 20 TNF agonists, CRF agonists, CRF BP antagonists, urocortin agonists, p3 agonists, ^ MSH (melanocyte-stimulating hormone) agonists, CCK agonists, serotonin-reuptake inhibitors, mixed serotonin and noradrenergic compounds, 5HT agonists, bombesin agonists, galanin antagonists, growth hormones, growth hormone-releasing compounds, TRH agonists, decoupling protein 2 or 3 modulators, leptin agonists, DA 25 agonists (bromocriptine, doprexin), lipase/amylase inhibitors, PPAR modulators, RXR modulators or TR-p-agonists or amphetamines.
9. A compound as claimed in one or more of claims 1 to 4 for use as a medicament for the treatment of impaired lipid metabolism. 30
10. A process for preparing a medicament comprising one or more of the REPLACEMENT SHEET (RULE 26) 5 3 7 5 « ^ 65 compounds as claimed in one or more of claims 1 to 4, which comprises mixing the active compound with a pharmaceutically acceptable carrier and bringing this mixture into a form suitable for administration. 5 '
11. The use of the compounds as claimed in one or more of claims 1 to 4 for preparing a medicament for treating hyperlipidemia.
12. The use of the compounds as claimed in one or more of claims 1 to 4 for preparing a medicament for lowering the serum cholesterol concentration. i ~
13. The use of the compounds as claimed in one or more of claims 1 to 4 for preparing a medicament for treating arteriosclerotic manifestations.
14. The use of the compounds as claimed in one or more of claims 1 to 4 for 15 preparing a medicament for treating insulin resistance. REPLACEMENT SHEET (RULE 26) 66
15. A compound according to claim 1, substantially as herein described or exemplified.
16. A medicament according to claim 5, substantially as herein described or exemplified.
17. A medicament according to claim 6, substantially as herein described or exemplified.
18. A process according to claim 10, substantially as herein described or exemplified.
19. A use according to claim 11, substantially as herein described or exemplified.
20. A use according to claim 12, substantially as herein described or exemplified.
21. A use according to claim 13, substantially as herein described or exemplified.
22. A use according to claim 14, substantially as herein described or exemplified.
NZ537304A 2002-06-19 2003-06-04 Ring-substituted diphenyl azetidinones, method for the production thereof, medicaments containing said compounds, and use thereof NZ537304A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10227506A DE10227506A1 (en) 2002-06-19 2002-06-19 Ring-substituted diphenylazetidinones, processes for their preparation, pharmaceutical compositions containing them and their use
PCT/EP2003/005815 WO2004000804A1 (en) 2002-06-19 2003-06-04 Ring-substituted diphenyl azetidinones, method for the production thereof, medicaments containing said compounds, and use thereof

Publications (1)

Publication Number Publication Date
NZ537304A true NZ537304A (en) 2005-10-28

Family

ID=29719281

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ537304A NZ537304A (en) 2002-06-19 2003-06-04 Ring-substituted diphenyl azetidinones, method for the production thereof, medicaments containing said compounds, and use thereof

Country Status (30)

Country Link
EP (1) EP1517892B1 (en)
JP (1) JP2005533072A (en)
CN (1) CN1662493A (en)
AR (1) AR039689A1 (en)
AT (1) ATE478842T1 (en)
AU (1) AU2003242616B2 (en)
BR (1) BR0311940A (en)
CA (1) CA2490109A1 (en)
DE (2) DE10227506A1 (en)
EC (1) ECSP045498A (en)
HN (1) HN2003000183A (en)
HR (1) HRP20041203A2 (en)
IL (1) IL165791A0 (en)
MA (1) MA27252A1 (en)
MX (1) MXPA04012236A (en)
MY (1) MY135850A (en)
NO (1) NO20050073L (en)
NZ (1) NZ537304A (en)
OA (1) OA12868A (en)
PA (1) PA8576001A1 (en)
PE (1) PE20040577A1 (en)
PL (1) PL372690A1 (en)
RS (1) RS108504A (en)
RU (1) RU2315754C2 (en)
SV (1) SV2004001549A (en)
TN (1) TNSN04255A1 (en)
TW (1) TW200404774A (en)
UY (1) UY27851A1 (en)
WO (1) WO2004000804A1 (en)
ZA (1) ZA200409381B (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
US7447226B2 (en) * 2003-10-31 2008-11-04 International Business Machines Corporation Methods and apparatus for continuous connectivity between mobile device and network using dynamic connection spreading
WO2005061452A1 (en) 2003-12-23 2005-07-07 Astrazeneca Ab Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity
CN101115726A (en) 2004-12-03 2008-01-30 先灵公司 Substituted piperazines as CB1 antagonists
WO2006107936A1 (en) * 2005-04-04 2006-10-12 Pontificia Universidad Catolica De Chile The use of ezetimibe in the prevention and treatment of cholesterol gallstones
ATE450526T1 (en) 2005-06-20 2009-12-15 Schering Corp PIPERIDINE DERIVATIVES SUITABLE AS ANTAGONISTS OF HISTAMINE H3
SA06270191B1 (en) 2005-06-22 2010-03-29 استرازينيكا ايه بي Novel 2-Azetidinone Derivatives as Cholesterol Absorption Inhibitors for the Treatment of Hyperlipidaemic Conditions
TW200811098A (en) 2006-04-27 2008-03-01 Astrazeneca Ab Chemical compounds
BRPI0715160A2 (en) 2006-08-08 2013-06-11 Sanofi Aventis arylamimoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, drugs comprising these compounds, and their use
BRPI0718052A2 (en) * 2006-11-02 2015-06-16 Sanofi Aventis Deutschland Diphenylazotidinone substituted by piperazine-1 sulfonic acid and having improved pharmacological properties
DE102007002260A1 (en) 2007-01-16 2008-07-31 Sanofi-Aventis Use of substituted pyranonic acid derivatives for the preparation of medicaments for the treatment of the metabolic syndrome
EP2025674A1 (en) 2007-08-15 2009-02-18 sanofi-aventis Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
DE102007054497B3 (en) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Novel crystalline diphenylazetidinone hydrates and process for their preparation
US8470841B2 (en) 2008-07-09 2013-06-25 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2010100255A1 (en) 2009-03-06 2010-09-10 Lipideon Biotechnology Ag Pharmaceutical hypocholesterolemic compositions
CN101993403B (en) 2009-08-11 2012-07-11 浙江海正药业股份有限公司 Azetidinone compound and medical applications thereof
ES2443016T3 (en) 2009-08-26 2014-02-17 Sanofi New crystalline hydrates of heteroaromatic fluoroglycosides, pharmaceutical products comprising these compounds, and their use
EP2582709B1 (en) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
EP2683705B1 (en) 2011-03-08 2015-04-22 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120052A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
EP2683704B1 (en) 2011-03-08 2014-12-17 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) * 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
CZ293957B6 (en) * 1995-10-31 2004-08-18 Scheringácorporation Hypocholesterolemic sugar-substituted 2-azetidinones, pharmaceutical composition and a kit containing thereof
DE10042447A1 (en) * 2000-08-29 2002-03-28 Aventis Pharma Gmbh Vertebrate intestinal protein that absorbs cholesterol and use of this protein to identify inhibitors of intestinal cholesterol transport

Also Published As

Publication number Publication date
JP2005533072A (en) 2005-11-04
RS108504A (en) 2007-02-05
EP1517892A1 (en) 2005-03-30
HRP20041203A2 (en) 2005-06-30
EP1517892B1 (en) 2010-08-25
OA12868A (en) 2006-09-15
RU2005101091A (en) 2005-07-10
AR039689A1 (en) 2005-03-09
RU2315754C2 (en) 2008-01-27
TW200404774A (en) 2004-04-01
HN2003000183A (en) 2003-08-01
IL165791A0 (en) 2006-01-15
DE10227506A1 (en) 2004-01-08
TNSN04255A1 (en) 2007-03-12
CA2490109A1 (en) 2003-12-31
AU2003242616A1 (en) 2004-01-06
DE50313017D1 (en) 2010-10-07
ECSP045498A (en) 2005-03-10
MA27252A1 (en) 2005-03-01
CN1662493A (en) 2005-08-31
BR0311940A (en) 2005-04-05
NO20050073L (en) 2005-01-06
PA8576001A1 (en) 2004-02-07
MXPA04012236A (en) 2005-02-25
SV2004001549A (en) 2004-03-19
PE20040577A1 (en) 2004-10-11
ATE478842T1 (en) 2010-09-15
MY135850A (en) 2008-07-31
WO2004000804A1 (en) 2003-12-31
AU2003242616B2 (en) 2008-12-11
PL372690A1 (en) 2005-07-25
UY27851A1 (en) 2003-12-31
ZA200409381B (en) 2006-05-31

Similar Documents

Publication Publication Date Title
CA2431983C (en) Novel 1,2-diphenylazetidinones, processes for their preparation, medicaments comprising these compounds and their use for treating impaired lipid metabolism
NZ537304A (en) Ring-substituted diphenyl azetidinones, method for the production thereof, medicaments containing said compounds, and use thereof
RU2287522C2 (en) Diphenylazethidinones substituted with acidic groups, method for their preparing, medicinal agent comprising thereof and their using
AU2003238209A1 (en) Cationically substituted diphenyl azetidinones, method for their production, medicaments containing said compounds and use thereof
US7176194B2 (en) Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
ZA200304093B (en) Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism.
NZ537302A (en) Diphenyl azetidinones substituted by acidic groups, method for their production, medicaments containing said compounds and use thereof
NZ537303A (en) Cationically substituted diphenyl azetidinones, method for their production, medicaments containing said compounds and use thereof
KR20050016583A (en) Ring-substituted diphenyl azetidinones, method for the production thereof, medicaments containing said compounds, and use thereof

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)